

CITATION REPORT

List of articles citing

Clinical assessment of body hair growth in women

DOI: 10.1210/jcem-21-11-1440

Journal of Clinical Endocrinology and Metabolism,
1961, 21, 1440-7.

Source: <https://exaly.com/paper-pdf/7784651/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1936	Endocrine disorders. 31-40		
1935	CHROMOSOMES IN GERMINAL APLASIA. 1963 , 282, 886		2
1934	LYONISATION OF THE X CHROMOSOME. 1963 , 2, 885-6		0
1933	HIRSUTISM AS A GYNECOLOGIC PROBLEM. 1963 , 87, 372-80		2
1932	Plagues in Animal Populations [Abridged]: Some Factors Affecting Hair Growth in Man. 1965 , 58, 802-804		
1931	The significance of the polycystic ovary. 1972 , 48, 20-3		1
1930	Hair growth in a patient with hirsutism: poor response to ovarian suppression. 1973 , 13, 246-9		
1929	Evidence for an underlying adrenocortical abnormality in hirsute women. 1974 , 3, 457-63		12
1928	The monocystic ovary syndrome. 1975 , 4, 621-2		7
1927	Cyproterone acetate: a study involving two volunteers with idiopathic hirsutism. 1975 , 4, 65-73		19
1926	Urinary pregnanetriol excretion in hirsutism. 1977 , 80, 373-9		3
1925	The treatment of hirsutism with cyproterone acetate (an anti-androgen). 1977 , 84, 119-23		20
1924	An assessment of (1) cyproterone acetate and (2) ethinyl oestradiol and lynoestrenol (Minilyn) in the treatment of idiopathic hirsutism. 1978 , 99, 545-52		9
1923	Further clinical experience in the treatment of hirsutism with cyproterone acetate. 1979 , 86, 139-41		18
1922	The inheritance of polycystic ovarian disease and a possible relationship to premature balding. 1979 , 11, 291-300		130
1921	The influence of long-term treatment with cyproterone acetate or a cyproterone acetate-ethinyl oestradiol combination on androgen levels in blood of hirsute women. 1980 , 12, 499-501		13
1920	TESTOSTERONE AND HUMAN SKIN. 1981 , 397-414		

1919	Hirsutism: implications, etiology, and management. 1981 , 140, 815-30	757
1918	Hirsutism. 1982 , 3, S25-S29	3
1917	Reduced dose of oestrogen in combination with cyproterone acetate in the treatment of hirsutism. 1982 , 3, 62-63	1
1916	Adrenal function in women with idiopathic acne. 1982 , 78, 468-71	18
1915	Idiopathic hirsutism: correlation of severity of hirsutism with degree of hyperandrogenism. 1982 , 23, 18-23	2
1914	Management of hirsutism. 1982 , 23, 97-104	1
1913	Management of the hirsute woman. 1983 , 22, 265-72	4
1912	Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. 1983 , 6, 23-7	30
1911	Hirsute women with elevated androgen levels: Psychological characteristics, steroid hormones, and catecholamines. 1983 , 2, 86-93	18
1910	The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients. 1983 , 59, 17-20	21
1909	Anxiety and hirsutism. 1983 , 53, 827-30	27
1908	Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism. 1983 , 104, 222-6	5
1907	Cyproterone acetate and the treatment of hirsutism. 1983 , 23, 93-8	3
1906	Evidence for adrenal and/or ovarian dysfunction as a possible etiology of idiopathic hirsutism. 1983 , 147, 57-63	13
1905	Anti-Androgen Treatment of Hirsute Women: A Study on Stress Responses. 1984 , 3, 79-92	4
1904	The effect of endogenous progesterone on serum levels of 5 alpha-reduced androgens in hirsute women. 1984 , 21, 383-92	9
1903	A study of body hair density and distribution in normal women. 1984 , 64, 179-84	17
1902	Body hair growth in women: normal or hirsute. 1984 , 64, 307-13	32

1901	Steroid hormone receptors in adrenal cortical carcinoma. 1984 , 150, 326-7	7
1900	The effects of benzodiazepines on hormones in women with idiopathic hirsutism. 1984 , 8, 11-7	2
1899	Androgen metabolism in hirsute patients treated with cyproterone acetate. 1984 , 20, 757-61	50
1898	Clinical and biochemical evaluation of patients with hirsutism. 1984 , 24, 23-9	4
1897	Polycystic ovarian disease: current concepts of pathophysiology and therapy. 1984 , 42, 667-82	50
1896	The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. 1985 , 43, 200-5	118
1895	Increased 5 β -reductase activity in idiopathic hirsutism**Supported in part by National Institutes of Health grant HD 17519-01A1.âPresented in part at the Fortieth Annual Meeting of The American Fertility Society, April 2 to 7, 1984, New Orleans, Louisiana.. 1985 , 43, 74-78	112
1894	The effects of spironolactone on adrenal steroidogenesis in hirsute women. 1985 , 44, 595-9	28
1893	Androgen receptor characteristics in skin fibroblasts from hirsute women. 1985 , 84, 62-5	13
1892	The treatment of hirsutism: experience with cyproterone acetate and spironolactone. 1985 , 26, 19-24	5
1891	Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. 1985 , 92, 983-5	32
1890	Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. 1985 , 112, 124-5	95
1889	Ultrasound study of ovarian and uterine morphology in women with polycystic ovary syndrome before, during and after treatment with cyproterone acetate and ethinyloestradiol. 1985 , 237, 1-10	7
1888	The effect of spironolactone on hirsutism and female androgen metabolism. 1985 , 23, 161-7	34
1887	The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. 1985 , 22, 29-36	53
1886	Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. 1985 , 109, 522-9	16
1885	Beta-endorphin basal levels in hirsute women. 1985 , 20, 373-80	4
1884	Spontaneous progression of small carotid atheroma detected by echotomography. 1985 , 2, 559-60	6

1883	The effect of spironolactone on genital skin 5 alpha-reductase activity. 1985 , 23, 191-4	40
1882	The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women. 1986 , 24, 361-8	6
1881	Prolactin modulates peripheral androgen metabolism**Supported in part by grants HD 17519-01A1 and RR-0043 from the National Institutes of Health.. 1986 , 45, 41-46	22
1880	Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study**Sponsored by the Canadian Fertility Research Association and funded by a grant-in-aid from Berlen Laboratories Limited, Canada.âThe following collaborators participated in this study: Peter Garner, M.D., University of Ottawa; Barbara Cruickshank, M.D., University of Western Ontario; Yousef Almalk, M.D., University of Sherbrooke; Tadas Tuljash, M.D., M.Sc., University of Alberta; Maria Psoure, M.D., UVA. 1986 , 46, 101-10	62
1879	The role of testosterone measurement in the investigation of androgen disorders. 1986 , 23 (Pt 2), 113-34	32
1878	Measurements of 3 alpha,17 beta-androstanediol glucuronide in serum and urine and the correlation with skin 5 alpha-reductase activity. 1986 , 46, 222-6	71
1877	Role of serum androgens and sex hormone binding globulin capacity in the evaluation of hirsutism in women. 1986 , 19, 58-61	16
1876	Measurement of hair growth. 1986 , 11, 127-38	22
1875	Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease. 1986 , 111, 228-34	11
1874	Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. 1986 , 293, 355-9	639
1873	Hair growth and androgen responses in hirsute women treated with continuous cyproterone acetate and cyclical ethinyl oestradiol. 1987 , 116, 497-501	4
1872	Normal hair growth in children. 1987 , 4, 173-84	47
1871	Hirsutism, polycystic ovarian disease, and ovarian 17-ketosteroid reductase deficiency. 1987 , 316, 1295-301	39
1870	The vellus index: a new method of assessing hair growth. 1987 , 48, 1064-6	6
1869	Hirsutism. 1987 , 294, 369-83	
1868	Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism. 1987 , 25, 209-19	4
1867	Spironolactone in the treatment of hirsutism. 1987 , 240, 95-100	4
1866	Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. 1987 , 94, 358-65	12

1865	Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome. 1987 , 26, 197-203	20
1864	Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. 1987 , 27, 703-13	31
1863	Serum androstenediol glucuronide concentrations in normal and hirsute women and patients with thyroid dysfunction. 1988 , 29, 529-38	30
1862	Effects of antiandrogen-estrogen treatment on sexual and endocrine parameters in hirsute women. 1988 , 17, 421-9	7
1861	Biomedical versus cultural constructions of abnormality: the case of idiopathic hirsutism in the United States. 1988 , 12, 219-38	14
1860	Acanthosis nigricans, insulin resistance and cutaneous virilism. 1988 , 118, 613-9	36
1859	Clinical markers of androgenicity in acne vulgaris. 1988 , 119, 723-30	24
1858	Spironolactone therapy for hirsute women. 1988 , 119, 17-17	2
1857	Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome. 1988 , 11, 637-40	11
1856	Prevalence of late-onset adrenal hyperplasia in postmenarchal hirsutism. 1988 , 11, 675-8	7
1855	Alopecia and hirsuties. Current concepts in pathogenesis and management. 1988 , 35, 83-91	12
1854	Polycystic ovaries--a common finding in normal women. 1988 , 1, 870-2	597
1853	Practical guidelines for the treatment of infertility in hirsute women. 1988 , 29, 143-52	
1852	Androgen parameters in hirsute women: correlations with body mass index and age. 1988 , 50, 255-9	8
1851	Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages. 1988 , 50, 260-5	26
1850	Ciclosporin-associated hypertrichosis is not related to sex hormone levels following renal transplantation. 1988 , 50, 199-204	11
1849	Spironolactone is an effective and well tolerated systemic antiandrogen therapy for Hirsute women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989 , 68, 966-70	5.6 65
1848	Lack of effect of spironolactone on hair shaft diameter in hirsute females. 1989 , 65, 459-62	20

1847	Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism. 1989 , 3, 281-8	9
1846	Salivary free testosterone in hirsutism. 1989 , 26 (Pt 6), 522-6	10
1845	Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. 1989 , 30, 459-70	364
1844	An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin. 1989 , 31, 345-53	15
1843	A chemiluminescent immunoassay for the direct measurement of urinary 5 alpha-androstane-3 alpha, 17 beta-diol-glucuronide in urine. 1989 , 4, 575-9	2
1842	Acne is not associated with abnormal plasma androgens. 1989 , 120, 649-54	44
1841	Cyproterone acetate in the treatment of hirsute women. 1989 , 121, 31-31	1
1840	Most women with acne have polycystic ovaries. 1989 , 121, 675-80	48
1839	Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals--experiences with a novel androgen receptor blocker. 1989 , 14, 361-3	3
1838	Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome. 1989 , 161, 1704-9	32
1837	Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease. 1989 , 52, 42-50	21
1836	Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and nonresponders. 1989 , 51, 30-4	80
1835	Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease. 1989 , 4, 136-9	115
1834	Treatment of hirsutism with cimetidine: a prospective randomized controlled trial. 1989 , 51, 247-50	15
1833	Relative diagnostic value of serum non-SHBG-bound testosterone, free androgen index and free testosterone in the assessment of mild to moderate hirsutism. 1989 , 26 (Pt 4), 311-6	32
1832	The polycystic ovary syndrome. 1989 , 29, 403-16	14
1831	Hirsutism in the adolescent female. 1989 , 36, 581-99	9
1830	THE MEDICAL TREATMENT OF MILD ENDOMETRIOSIS. 1989 , 68, 27-30	14

1829	Psychosomatic assessment of hirsute women. 1989 , 51, 96-100	24
1828	Hirsutism: Authors' reply. 1990 , 301, 1215-1215	
1827	Hirsutism.. 1990 , 301, 1215-1216	
1826	Hirsutism. 1990 , 301, 1215-1216	1
1825	Selling the pathology service. 1990 , 301, 1214-1215	
1824	Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism. 1990 , 53, 765-79	46
1823	Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women. 1990 , 54, 245-50	20
1822	Effect of naloxone on plasma insulin, insulin-like growth factor I, and its binding protein 1 in patients with polycystic ovarian disease. 1990 , 54, 434-7	15
1821	Ketoconazole use in the treatment of ovarian hyperandrogenism**Presented at the 71st Annual Meeting of the Endocrine Society, Seattle, Washington, June 21 to 24, 1989.. 1990 , 54, 438-444	11
1820	Do clinical markers of hyperandrogenism relate to the response of acne to conventional therapy?. 1990 , 1, 127-129	
1819	Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects. 1990 , 53, 40-4	18
1818	Ketoconazole therapy for women with acne and/or hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 71, 335-9	5.6 35
1817	Hirsutism in a gynaecological context. 1990 , 30, 153-6	1
1816	Incidence of polycystic ovaries in patients with late-onset or persistent acne: hormonal reports. 1990 , 181, 109-11	18
1815	Androgen excess in women with acne alone compared with women with acne and/or hirsutism. 1990 , 94, 279-83	55
1814	Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. 1990 , 32, 213-20	291
1813	Hormonal studies on women with polycystic ovaries diagnosed by ultrasound. 1990 , 32, 467-74	19
1812	Preliminary results suggesting exaggerated ovarian androgen production early in the course of polycystic ovary syndrome. 1990 , 11, 480-4	4

1811	[Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate]. 1990 , 68, 597-601		16
1810	Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgen. 1990 , 36, 283-289		67
1809	Hirsutism. 1990 , 301, 1215-1215		
1808	Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. 1990 , 323, 855-63		114
1807	ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism. 1990 , 323, 849-54		92
1806	Study of the source(s) of hyperandrogenism in women with idiopathic hirsutism. 1990 , 22, 499-503		2
1805	Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 1096-102	5.6	87
1804	Assessment of the one hour adrenocorticotrophic hormone test in the diagnosis of attenuated 21-hydroxylase deficiency. 1990 , 43, 493-5		9
1803	Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 71, 8-14	5.6	51
1802	Steroidogenesis in an estrogen-producing adrenal tumor in a young woman: comparison with steroid profiles associated with cortisol- and androgen-producing tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 28-34	5.6	30
1801	Hirsutism: definitions and etiology. 1990 , 22, 99-103		11
1800	Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 642-6	5.6	118
1799	Low-dose ketoconazole treatment in hirsute women. 1990 , 13, 35-40		13
1798	Evaluation of clinical and hormonal effects in hirsute women treated with ketoconazole. 1990 , 13, 867-70		4
1797	Antiandrogens: clinical applications. 1990 , 37, 349-62		30
1796	Hirsutism. 1990 , 1, 185-8		2
1795	Postmenopausal androgen secreting ovarian tumour: pathophysiological implications; a case report. 1990 , 35, 97-105		4
1794	Glucocorticoid therapy in hyperandrogenism. 1990 , 4, 457-71		7

1793	Treatment of hirsutism with the pure antiandrogen flutamide. 1990 , 23, 462-9		111
1792	Hirsutism in women with chronic psychiatric illness. 1990 , 27, 460-1		6
1791	Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. 1990 , 42, 611-9		46
1790	Is plasma 5 alpha-androstane 3 alpha, 17 beta-diol glucuronide a biochemical marker of hirsutism in women?. 1991 , 39, 55-61		15
1789	Transvaginal sonography and abnormal ovarian appearance in menstrual cycle disturbances. 1991 , 17, 589-93		49
1788	Response of gonadotropins to pituitary stimulation with luteinizing hormone releasing hormone is a more specific than sensitive parameter for the polycystic ovary syndrome. 1991 , 5, 235-47		3
1787	Selective venous catheterization in the evaluation of hyperandrogenism. 1991 , 14, 949-56		26
1786	Hirsutism: pilosebaceous unit dysregulation. Role of peripheral and glandular factors. 1991 , 14, 153-70		15
1785	Hirsutography: Photographic measurement of linear hair growth in hirsute women during comparison of anti-androgen treatments. 1991 , 11, 63-67		4
1784	Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 1242-8	5.6	151
1783	Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. 1991 , 44, 113-24		23
1782	Flutamide in the treatment of hirsutism. 1991 , 36, 155-7		22
1781	Inverse relation between density of nevi and terminal cutaneous hair. Study of male volunteer subjects and patients enrolled in a dysplastic nevus syndrome registry. 1991 , 24, 418-22		1
1780	The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. 1991 , 155, 677-80		28
1779	Predictors of clinical response in hirsute women treated with spironolactone. 1991 , 55, 1076-81		23
1778	Ovarian hyperandrogenism: the role of and sensitivity to gonadotropins**Presented in part at the 35th Annual Meeting of the Society for Gynecological Investigation, Baltimore, Maryland, March 17 to 20, 1988.âSupported in part by a grant from the Pangborn Fund, University of Maryland School of Medicine, Baltimore, Maryland. 1991 , 55, 73-79		14
1777	Effect of the gonadotrophin releasing hormone analogue, goserelin, and oestradiol replacement on sebum excretion rates and hair size in mildly hirsute women. 1991 , 1, 289-292		2
1776	Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17âestradiol*âSupported in part by National Research Council (C.N.R.), grant 88.0035711, Rome, Italy.âPresented in part at the 70th Annual Meeting of the Endocrine Society, New Orleans, Louisiana, June 8 to 11, 1988. 1991 , 55, 742-745		18

1775	Oestrogen and androgen states in oligo-amenorrhoeic women with polycystic ovaries. 1991 , 98, 294-9		16
1774	Polycystic ovaries: do these represent a specific endocrinopathy?. 1991 , 98, 300-5		6
1773	The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. 1991 , 34, 127-31		104
1772	Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. 1991 , 35, 5-10		77
1771	Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome. 1991 , 124, 370-4		9
1770	Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 811-7	5.6	126
1769	Effects of ketoconazole in hirsute women. 1991 , 124, 19-22		17
1768	Assessment of the adrenal-ovarian contribution by short-term dexamethasone and ACTH tests in hyperandrogenized patients. 1991 , 5, 37-48		4
1767	Psychological morbidity of hirsute women. 1991 , 11, 198-203		2
1766	Body Hair Distribution in Adolescent Girls: Correlation with Salivary Testosterone. 1991 , 4,		
1765	Adrenal androgen secretion in postadolescent acne: increased adrenocortical function without hypersensitivity to adrenocorticotropin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 380-4	5.6	23
1764	Polycystic ovarian syndrome and associated hirsutism in the adolescent. 1992 , 5, 231-241		6
1763	ACP Broadsheet 131: March 1992. Hirsute women: should they be investigated?. 1992 , 45, 188-92		4
1762	Androgen-producing bilateral large cortical adrenal adenomas associated with polycystic ovaries in a young female. 1992 , 68, 219-22		5
1761	Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrhoeic women with or without polycystic ovaries. 1992 , 58, 697-702		22
1760	Assessment of clinical hyperandrogenism in adolescent girls. 1992 , 5, 13-20		4
1759	Nonclassical 3 β -hydroxysteroid dehydrogenase deficiency: a review of our experience with 25 female patients**Supported by United States Public Health Service, National Institutes of Health, Bethesda, Maryland, grant awards HD00072 and RR 06020. Support was also received from the United Jewish Appeal: Federation of Jewish Philanthropies of New York, Inc; and the Reichman		22
1758	Cutaneous application of an androstenedione gel as an in vivo test of 5 alpha-reductase activity in women. 1992 , 58, 708-12The Endocrine Society. 1992 , 58, 129-136		12

1757	Treatment of hirsutism in women with flutamide. 1992 , 57, 543-7	62
1756	Hyperandrogenism--what is normal?. 1992 , 327, 194-6	7
1755	The incidence of non-classical 21-hydroxylase deficiency in hirsute adolescent girls. 1992 , 6, 99-106	15
1754	HLADR5 and C4BQO high frequency and antinuclear antibodies positivity in patients with 21 hydroxylase deficiency from Campania region. 1992 , 15, 429-36	3
1753	Plasma levels of C19 steroid glucuronides in pre-menopausal women with non-classical congenital adrenal hyperplasia. 1992 , 42, 211-21	7
1752	Dehydroepiandrosterone sulfate and other possible influencing factors that modulate sex hormone-binding globulin levels in the hirsute patient. 1992 , 42, 607-11	5
1751	Hyperinsulin ^h mie post-stimulative et androg ^h ães plasmatiques chez la femme ob ^h ãe. 1992 , 6, 203-208	
1750	The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women. 1992 , 36, 383-8	24
1749	Investigation of adrenal function in women with oligomenorrhoea and hirsutism (clinical PCOS) from the north-east of England using an adrenal stimulation test. 1992 , 36, 389-97	26
1748	Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. 1992 , 36, 537-43	100
1747	Increased free testosterone but normal 5 alpha-reduced testosterone metabolites in obese premenopausal women. 1992 , 36, 553-8	16
1746	17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. 1992 , 36, 565-71	56
1745	Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. 1992 , 36, 105-11	686
1744	Late-onset congenital adrenal hyperplasia in women with hirsutism. 1992 , 22, 651-8	16
1743	Prevalence of nonclassical congenital adrenal hyperplasia among women self-referred for electrolytic treatment of hirsutism. 1992 , 42, 197-200	4
1742	Semiquantitative assessment of hirsutism in Dutch women. 1993 , 128, 259-63	22
1741	Hirsutism. 1993 , 32, 773-7	11
1740	The relation between clinical manifestations of polycystic ovary syndrome and beta-cell function. 1993 , 38, 295-300	19

1739	Serum FSH bioactivity and response to acute gonadotrophin releasing hormone (GnRH) agonist stimulation in patients with polycystic ovary syndrome (PCOS) as compared to control groups. 1993 , 38, 311-20	4
1738	The treatment of women with hirsutism. 1993 , 39, 143-50	19
1737	The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. 1993 , 39, 157-62	57
1736	Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 1993 , 38, 653-8	234
1735	Hormonal and clinic evaluation of patients with moderate body hair growth. 1993 , 48, 47-56	2
1734	Psychological morbidity in women referred for treatment of hirsutism. 1993 , 37, 615-9	85
1733	Hirsutism. Practical therapeutic guidelines. 1993 , 45, 223-31	10
1732	Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. 1993 , 16, 675-7	22
1731	Hirsutism and the effectiveness of spironolactone in its management. 1993 , 16, 925-32	20
1730	Insulin sensitivity and blood pressure in non-obese normotensive patients with hyperandrogenism. 1993 , 341, 1226	
1729	Autism and megalencephaly. 1993 , 341, 1225-6	141
1728	Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog. 1993 , 42, 147-53	14
1727	Pulsatile secretion of serum gonadotropins in hirsute women with and without polycystic ovarian syndrome. 1993 , 687, 136-49	1
1726	Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome. 1993 , 687, 255-62	5
1725	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1993. A 56-year-old woman with virilization. 1993 , 328, 1770-6	7
1724	Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. 1993 , 7, 273-7	33
1723	Hormonal status and clinical relevance of hirsutism in elderly women. 1993 , 129, 307-10	2
1722	Quality of life of hirsute women. 1993 , 69, 186-9	122

1721	Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. 1993 , 59, 544-9	80
1720	Literature reviews. 1993 , 6, 105-110	
1719	Flutamide--effects and side effects. 1993 , 59, 937	1
1718	Idiopathic hirsutism or polycystic ovary syndrome?. 1993 , 33, 414-6	17
1717	Management of the transfer cycle--after freeze/thaw. 1993 , 59, 936-7	3
1716	Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist. 1993 , 8, 2027-32	27
1715	Dermatologic and Cosmetic Concerns of the Older Woman. 1993 , 9, 209-229	36
1714	Efficacy of chronic therapy with the gonadotrophin releasing hormone agonist decapeptyl in patients with polycystic ovary syndrome. 1994 , 9, 1048-52	8
1713	Bedside Assessment of Skin-Fold Thickness. 1994 , 154, 777	10
1712	Identification of virilizing adrenal tumors in hirsute women. 1994 , 331, 968-73	126
1711	Lipid profiles in women with hirsutism and polycystic ovaries. 1994 , 8, 33-7	13
1710	Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. 1994 , 330, 460-5	171
1709	Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. 1994 , 41, 571-6	90
1708	Androgens and human hair growth. 1994 , 40, 439-57	130
1707	A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. 1994 , 41, 231-6	115
1706	Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. 1994 , 41, 463-71	171
1705	The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. 1994 , 41, 473-81	146
1704	The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. 1994 , 34, 67-72	151

1703	The clinical usefulness of 3 alpha-androstanediol glucuronide in premenopausal women with hirsutism. 1994 , 34, 208-10	1
1702	Becker's nevus associated with chromosomal mosaicism and congenital adrenal hyperplasia. 1994 , 30, 655-7	30
1701	Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome. 1994 , 43, 1536-42	57
1700	Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. 1994 , 43, 706-13	94
1699	The use of flutamide in the management of hirsutism. 1994 , 17, 195-9	20
1698	Transvaginal ultrasonic assessment of the response to clomiphene citrate in polycystic ovarian syndrome. 1994 , 62, 48-53	11
1697	Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome*âSupported in part by Robert Wood Johnson Pharmaceuticals, New Brunswick, New Jersey.âPresented at the Society For Gynecologic Investigation, San Antonio, Texas, March 18 to 21, 1992.. 1994 , 61, 1027-1033	11
1696	Letters to the Editor. 1994 , 34, 498-501	
1695	The use of antiandrogen flutamide in the treatment of hirsutism. 1994 , 41, 573-7	11
1694	Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. 1994 , 61, 823-32	16
1693	Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. 1994 , 130, 333-8	24
1692	Hirsutism: a brief review. 1994 , 308, 289-94	6
1691	Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. 1994 , 61, 427-31	18
1690	Comparison of the efficacy of spironolactone**Spironolactone (Aldactone; Searle, Chicago, IL). versus flutamideâFlutamide (Eulexin; Schering Plough Laboratories, Heist, Belgium). in the treatment of hirsutismâPresented in part at the 3rd World Congress of Gynecology and Obstetrics, Madonna di Campiglio, Italy, February 9 to 16, 1992.. 1994 , 61, 615-616	61
1689	Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. 1994 , 61, 281-7	149
1688	Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. 1994 , 61, 817-22	42
1687	Serum levels of androstanediol glucuronide, total testosterone, and free testosterone in hirsute women. 1994 , 62, 76-80	7
1686	Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperandrogenism: role of adrenal and ovarian cytochrome P450c17 alpha. 1994 , 62, 521-30	29

1685	Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients. 1994 , 62, 1129-35	19
1684	Circulating tumor necrosis factor (TNF)-alpha in normally cycling women and patients with premature ovarian failure and polycystic ovaries. 1995 , 34, 170-5	41
1683	A twin study of polycystic ovary syndrome**Supported by The Academy of Finland, the University of Helsinki, the Nordisk Forsknings Kommitte and the Cancer Society of Finland (M.S.).. 1995 , 63, 478-486	123
1682	Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. 1995 , 10, 1951-6	38
1681	Screening of the mutations in luteinizing hormone beta-subunit in patients with menstrual disorders. 1995 , 63, 989-95	41
1680	Growth hormone, insulin-like growth factor-I axis, and insulin secretion in hyperandrogenic adolescents. 1995 , 64, 1113-1119	27
1679	Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. 1995 , 64, 299-306	68
1678	Ovarian morphology and insulin sensitivity in women with bulimia nervosa. 1995 , 43, 451-5	52
1677	Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. 1995 , 42, 475-81	61
1676	A gonadotrophin dependent stromal luteoma: a rare cause of post-menopausal virilization. 1995 , 43, 645-9	19
1675	Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. 1995 , 133, 249-53	44
1674	Partial lipodystrophy. 1995 , 34, 36-7	10
1673	Updating the clinical experience in endometriosis--the European perspective. 1995 , 102 Suppl 12, 12-6	18
1672	Hirsutism: evaluation and management. 1995 , 10, 283-92	7
1671	Bulimia nervosa and polycystic ovary syndrome. 1995 , 9, 113-7	39
1670	No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide. 1995 , 133, 718-22	15
1669	A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis. 1995 , 15, 188-194	19
1668	Insulin-like growth factor binding proteins in a natural pre-ovulatory follicle from a woman with polycystic ovary syndrome. 1995 , 10, 2248-52	8

1667	Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. 1995 , 9, 221-8	23
1666	Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. 1995 , 44, 525-31	99
1665	Androgenic disorders of women: diagnostic and therapeutic decision making. 1995 , 98, 120S-129S	13
1664	Evaluation and treatment of hirsute women. 1995 , 49, 341-346	3
1663	Hyperandrogenic chronic anovulation Number 202 â€¦February 1995. 1995 , 49, 201-208	2
1662	Polycystic ovary syndrome. 1995 , 333, 853-61	1576
1661	The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. 1995 , 18, 431-5	5
1660	New reliable biochemical marker for screening 21 alpha-hydroxylase deficiency without index person among hirsute women in agreement with HLA-haplotyping. 1995 , 18, 754-61	2
1659	Polycystic ovarian disease: current insights into an old problem. 1996 , 9, 3-8	1
1658	Pilot study of hirsutism in women with psychiatric disorders. 1996 , 39, 149-51	
1657	Low dose ketoconazole is an effective and a relatively safe alternative in the treatment of hirsutism. 1996 , 36, 487-9	8
1656	Body fat distribution, peripheral indicators of androgenic activity, and blood pressure in women. 1996 , 6, 181-7	6
1655	Follow-up study of adolescent girls with a history of premature pubarche. 1996 , 18, 301-5	23
1654	Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. 1996 , 53, 163-70	42
1653	Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. 1996 , 45, 24-7	22
1652	Menstrual history as a determinant of current bone density in young hirsute women. 1996 , 45, 515-8	16
1651	Value of buserelin testing in the evaluation of hirsute women. 1996 , 19, 204-9	8
1650	Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome. 1996 , 10, 311-8	20

1649	Polycystic ovary syndrome: clinical and laboratory evaluation. 1996 , 114, 1222-5	7
1648	Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. 1996 , 66, 216-9	44
1647	Serum free testosterone in polycystic ovary syndrome measured with a new reference method. 1996 , 65, 55-60	4
1646	Dose-response effect of depot leuprolide acetate on serum androgens in hirsute women. 1996 , 65, 912-5	8
1645	Finasteride in the treatment of hirsutism: new therapeutic perspectives. 1996 , 66, 61-5	47
1644	Serum 3 alpha-androstanediol-glucuronide is decreased in nonhirsute women with acne vulgaris. 1996 , 66, 1033-5	7
1643	Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. 1996 , 10, 249-55	26
1642	Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?. 1996 , 11, 23-8	138
1641	Adrenal steroidogenesis is related to insulin in hyperandrogenic women. 1996 , 66, 564-70	35
1640	Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. 1996 , 10, 119-23	26
1639	The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. 1996 , 66, 527-32	14
1638	The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: evidence from a large multicenter study in Spain. 1996 , 13, 551-6	23
1637	Plasma lipids, lipoproteins and apolipoproteins in hirsute women. 1996 , 75, 261-5	5
1636	Polycystic ovaries in pre and post-menopausal women. 1996 , 44, 269-76	37
1635	Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders. 1996 , 24, 243-8	24
1634	Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. 1996 , 134, 1057-1059	28
1633	Hirsutism in the United Arab Emirates: a hospital study. 1996 , 72, 168-71	13
1632	Interim Safety Analysis of a Two-Year Study Comparing Oral Estrogen-Androgen and Conjugated Estrogens in Surgically Menopausal Women. 1996 , 5, 593-602	32

1631	Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2283-8	5.6	156
1630	Augmentation of bone mineral density in hirsute women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2821-5	5.6	47
1629	Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 479-85	5.6	62
1628	Efficacy of combined ethinylloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome. 1997 , 17, 565-8		2
1627	Ovarian 17 alpha-hydroxyprogesterone responses to GnRH analog testing in oligomenorrheic insulin-dependent diabetic adolescents. 1997 , 136, 624-9		17
1626	Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms. 1997 , 12, 423-9		38
1625	Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2248-56	5.6	288
1624	Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. 1997 , 6, 397-402		215
1623	The clinical management of hirsutism. 1997 , 136, 339-48		29
1622	Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis. 1997 , 36, 433-9		16
1621	Treatment of androgen excess in females: yesterday, today and tomorrow. 1997 , 11, 411-33		7
1620	Color Doppler analysis in oligo- and amenorrheic women with polycystic ovary syndrome. 1997 , 11, 105-10		25
1619	Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. 1997 , 20, 519-26		99
1618	Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. 1997 , 10, 125-32		28
1617	Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. 1997 , 68, 1000-3		72
1616	Chronobiologic evolution of luteinizing hormone secretion in adolescence: developmental patterns and speculations on the onset of the polycystic ovary syndrome. 1997 , 67, 842-8		17
1615	Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. 1997 , 67, 849-55		76
1614	Different dysregulations in adrenal steroid biosynthesis as a prevalent cause of hyperandrogenism in women from southern Italy. 1997 , 68, 236-41		11

1613	Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. 1997 , 11, 251-7	29
1612	Inhibition of ovulation with transdermal estradiol and oral progestogens in perimenopausal women. 1997 , 55, 239-43	14
1611	Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. 1997 , 46, 437-40	26
1610	Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. 1997 , 46, 454-7	222
1609	Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?. 1997 , 46, 902-7	39
1608	Hirsutism. 1997 , 349, 191-5	72
1607	Fetal growth, length of gestation, and polycystic ovaries in adult life. 1997 , 350, 1131-5	195
1606	Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. 1997 , 126, 32-5	219
1605	Women with clinically significant hirsutism always have detectable endocrinological abnormalities. 1997 , 9, 226-231	2
1604	Adolescent polycystic ovary syndrome. 1997 , 816, 194-208	27
1603	Androgen producing luteinized granulosa cell tumor. 1997 , 76, 285-286	2
1602	A higher rate of hyperandrogenic disorders in female-to-male transsexuals. 1997 , 22, 361-80	68
1601	Post-adolescent acne: a review of clinical features. 1997 , 136, 66-70	29
1600	Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. 1997 , 46, 123-8	43
1599	Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. 1997 , 47, 93-9	217
1598	Spectrum of malignancy and premalignancy in Carney syndrome. 1997 , 73, 369-77	14
1597	GnRH agonists and add-back therapy: is there a perfect combination?. 1998 , 105, 475-85	44
1596	Managing hirsutism in gynaecological practice. 1998 , 105, 687-96	24

1595 Androgenisierungs-erscheinungen bei jungen M^ächen. **1998**, 31, 534-538

1594 Ruby laser treatment for hirsutism: clinical response and patient tolerance. **1998**, 138, 1009-14 44

1593 Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. **1998**, 49, 91-9 106

1592 Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome. **1998**, 49, 221-8 34

1591 Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne. **1998**, 48, 209-15 53

1590 Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. **1998**, 30, 1243-4 10

1589 Polycystic ovary syndrome. **1998**, 27, 877-902, ix 55

1588 Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. **1998**, 3, 79-84 19

1587 Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS. **1998**, 12, 223-9 7

1586 Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. **1998**, 21, 128-32 26

1585 Effect of finasteride in idiopathic hirsutism. **1998**, 21, 694-8 23

1584 Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3078-3082 5.6 464

1583 The plasminogen activator system in women with polycystic ovary syndrome. **1998**, 69, 236-41 104

1582 Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. **1998**, 69, 691-6 233

1581 Transient hyperandrogenemia and its relation to ovulation. **1998**, 70, 664-70 4

1580 Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. **1998**, 30, 43-7 98

1579 Serum levels of 3alpha-androstanediol glucuronide in hirsute and non hirsute women. **1998**, 138, 421-4 12

1578 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3078-82 5.6 1193

1577	Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 3558-62	5.6	400
1576	Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2566-8	5.6	66
1575	The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2580-4	5.6	37
1574	Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 1742-5	5.6	12
1573	Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 1976-87	5.6	169
1572	Decline in insulin-like growth factor I levels after clomiphene citrate does not correct hyperandrogenemia in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2394-8	5.6	7
1571	Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients. 1998 , 3, 29-33		9
1570	Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome. 1998 , 139, 621-30		36
1569	The prevalence of polycystic ovaries in healthy women. 1999 , 78, 137-141		67
1568	Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. 1999 , 14, 1949-52		54
1567	Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. 1999 , 14, 2223-9		72
1566	Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1091-5	5.6	71
1565	Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 415-23	5.6	102
1564	Corticotropin-releasing hormone: a potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4602-6	5.6	28
1563	Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. 1999 , 14, 2951-8		22
1562	Diagnostic difficulty in polycystic ovary syndrome due to an LH-beta-subunit variant. 1999 , 140, 235-8		5
1561	Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 38-43	5.6	147
1560	Hypertension and virilization caused by a unique desoxycorticosterone- and androgen-secreting adrenal adenoma. 1999 , 12, 215-20		12

1559	Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3030-5	5.6	76
1558	A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4629-36	5.6	28
1557	The prevalence of polycystic ovaries in healthy women. 1999 , 78, 137-141		6
1556	The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. 1999 , 50, 517-27		114
1555	Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche. 1999 , 51, 395-401		24
1554	Polycystic ovaries and associated clinical and biochemical features in young women. 1999 , 51, 779-86		259
1553	A review of 1019 consecutive cases of polycystic ovary syndrome demonstrated by ultrasound. 1999 , 43, 41-6		4
1552	Unwanted body hair and its removal: a review. 1999 , 25, 431-9		37
1551	Hilus cell tumour of the ovary in a virilized, premenopausal woman. Case report and review of hyperandrogenism of ovarian origin. 1999 , 39, 75-8		2
1550	[A hairy case]. 1999 , 94, 708-11		
1549	Doppler, ultrasonographic and endocrinological environment with regard to the number of small subcapsular follicles in polycystic ovary syndrome. 1999 , 13, 123-9		30
1548	Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. 1999 , 13, 344-51		36
1547	Hormones and hair patterning in men: a role for insulin-like growth factor 1?. 1999 , 40, 200-3		23
1546	Recurrence rate of hirsutism after 3 different antiandrogen therapies. 1999 , 41, 64-8		22
1545	Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrhic women with the polycystic ovary syndrome. 1999 , 48, 511-9		183
1544	Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. 1999 , 48, 1589-95		159
1543	Hair removal using a long-pulsed alexandrite laser. 1999 , 17, 387-99, ix		20
1542	Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. 1999 , 46, 519-43		46

1541	Antiandrogen treatment of polycystic ovary syndrome. 1999 , 28, 409-21	39
1540	Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. 1999 , 71, 122-8	34
1539	Obesity regulates bioavailable testosterone levels in women with or without polycystic ovary syndrome. 1999 , 71, 457-61	15
1538	Role of the mutations Trp8 => Arg and Ile15 => Thr of the human luteinizing hormone beta-subunit in women with polycystic ovary syndrome. 1999 , 71, 425-30	37
1537	Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. 1999 , 72, 41-6	30
1536	Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome. 1999 , 72, 26-31	7
1535	Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. 1999 , 72, 448-53	37
1534	The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. 1999 , 72, 629-38	58
1533	Computerized assessment of facial hair growth. 1999 , 72, 737-9	2
1532	Comparison of finasteride versus flutamide in the treatment of hirsutism. 1999 , 141, 361-7	53
1531	The prevalence of polycystic ovaries in women with infertility. 1999 , 14, 2720-3	78
1530	Increased peripheral androgen activity in infertile Korean women with polycystic ovaries. 1999 , 14, 1934-8	2
1529	Adipocyte insulin action following ovulation in polycystic ovarian syndrome. 1999 , 14, 2216-22	10
1528	Serum Androgen Levels and Muscle Mass in Women With Polycystic Ovary Syndrome. 1999 , 94, 337-340	4
1527	A clinical index for rating severity in Cushing's syndrome. 2000 , 69, 216-20	44
1526	Diffuse Stromal Leydig Cell Hyperplasia: A Unique Cause of Postmenopausal Hyperandrogenism and Virilization. 2000 , 75, 288-292	15
1525	The role of androgens in determining acne severity in adult women. 2000 , 143, 399-404	69
1524	The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. 2000 , 52, 81-6	125

1523	Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. 2000 , 52, 379-82		14
1522	Spironolactone as a single agent for long-term therapy of hirsute patients. 2000 , 52, 587-94		72
1521	Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. 2000 , 53, 523-7		37
1520	Ultrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS). 2000 , 26, 977-80		45
1519	Insulin, androgen, and gonadotropin concentrations, body mass index, and waist to hip ratio in the first years after menarche in girls with regular menstrual cycles, irregular menstrual cycles, or oligomenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1394-400	5.6	52
1518	Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3251-5	5.6	81
1517	Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. 2000 , 13, 253-9		33
1516	Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2913-21	5.6	144
1515	Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3526-30	5.6	142
1514	Premature adrenarche--normal variant or forerunner of adult disease?. 2000 , 21, 671-96		294
1513	High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 4182-7	5.6	70
1512	Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. 2000 , 15, 1266-74		165
1511	Idiopathic hirsutism. 2000 , 21, 347-62		174
1510	A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2434-8	5.6	906
1509	Clinical assessment and serum hormonal profile in prepubertal hypertrichosis. 2000 , 54, 20-5		17
1508	Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3161-8	5.6	176
1507	The SAHA syndrome. 2000 , 54, 251-8		51
1506	A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women From Spain. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2434-2438	5.6	766

1505	Diffuse stromal Leydig cell hyperplasia: a unique cause of postmenopausal hyperandrogenism and virilization. 2000 , 75, 288-92		14
1504	Bone mineral density in women with idiopathic hirsutism. 2000 , 14, 364-8		15
1503	Management of hirsutism. 2000 , 1, 89-99		37
1502	Polycystic ovary syndrome: a new ultrasonographic and color Doppler pattern. 2000 , 14, 417-24		10
1501	Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome. 2000 , 14, 337-41		4
1500	New treatments of hyperandrogenism and hirsutism. 2000 , 27, 567-81, vi-vii		7
1499	The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1735-40	5.6	64
1498	Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. 2000 , 74, 49-58		119
1497	Genotyping of the type II 3beta-hydroxysteroid dehydrogenase gene (HSD3B2) in women with hirsutism and elevated ACTH-stimulated delta(5)-steroids. 2000 , 74, 553-7		11
1496	Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. 2000 , 74, 1159-63		26
1495	Examination of the chin or lower abdomen only for the prediction of hirsutism. 2000 , 74, 980-3		18
1494	Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. 2000 , 73, 261-5		16
1493	Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. 2000 , 73, 718-23		45
1492	Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist. 2001 , 75, 59-62		11
1491	Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome. 2001 , 76, 506-10		26
1490	Facial and abdominal hair growth in hirsutism: a computerized evaluation. 2001 , 45, 846-50		19
1489	The prevalence of upper lip hair in black and white girls during puberty: a new standard. 2001 , 138, 134-6		23
1488	5 alpha-Reductase inhibitors. 2001 , 56, 143-80		5

1487	Hirsuties. 2001 , 19, 189-99	8
1486	Resistance to multiple steroids in two sisters. 2001 , 76, 161-6	15
1485	Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). 2001 , 29, 160-9	128
1484	Síndrome de ovarios poliquísticos: hiperinsulinemia relacionada con riesgo cardiovascular. 2001 , 28, 162-177	1
1483	[Hirsutism as presentation form of macroprolactinoma]. 2001 , 116, 36-7	0
1482	Polycystic ovary syndrome. A diagnostic challenge. 2001 , 28, 1-20	12
1481	Functional hyperandrogenism detected by corticotropin and GnRH-analogue stimulation tests in women affected by apparently idiopathic hirsutism. 2001 , 24, 491-8	17
1480	Testosterone-secreting gonadotropin-responsive adrenal adenoma and its treatment with the antiandrogen flutamide. 2001 , 24, 622-7	14
1479	Clinical use of 5 α -reductase inhibitors. 2001 , 571-596	3
1478	Skin manifestations of polycystic ovary syndrome. 2001 , 102-120	2
1477	Importância da dosagem da 17OH-progesterona na síndrome dos ovários policísticos. 2001 , 45, 361-368	1
1476	Risk factors for glucose intolerance in active acromegaly. 2001 , 34, 1429-33	61
1475	Androgens and hair: a biological paradox. 2001 , 207-232	9
1474	Topical finasteride therapy in hirsutism. 2001 , 7, 64-5	1
1473	Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. 2001 , 15, 381-8	4
1472	Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?. 2001 , 16, 940-4	32
1471	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders. 2001 , 7, 120-134	54
1470	Polycystic Ovary Syndrome. 2001 , 94, 190-196	1

1469	Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. 2001 , 54, 455-62		61
1468	Tissue insulin sensitivity and body weight in polycystic ovary syndrome. 2001 , 55, 191-9		30
1467	Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. 2001 , 55, 439-46		76
1466	Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. 2001 , 55, 667-72		105
1465	Successful reduction in skin damage resulting from exposure to the normal-mode ruby laser in an animal model. 2001 , 54, 144-50		8
1464	Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. 2001 , 184, 289-96		50
1463	Extraovarian steroid cell tumor 'not otherwise specified' as a rare cause of virilization in twelve-year-old girl. 2001 , 55, 254-7		5
1462	Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. 2001 , 16, 2066-72		39
1461	Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2591-9	5.6	26
1460	Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 3595-8	5.6	123
1459	Androgen secretion in ectopic ACTH syndrome and in Cushing's disease: modifications before and after surgery. 2001 , 33, 596-601		12
1458	Ovarian morphology and serum hormone markers as predictors of ovarian follicle recruitment by gonadotropins for in vitro fertilization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2538-43	5.6	30
1457	Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2428-36	5.6	10
1456	Characterization of reproductive endocrine disorders in women with epilepsy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2950-6	5.6	76
1455	Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 207-13	5.6	104
1454	Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. 2001 , 16, 2546-51		31
1453	Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. 2002 , 57, 101-6		44
1452	Quality of life in adolescent girls with polycystic ovary syndrome. 2002 , 156, 556-60		112

1451	Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. 2002 , 16, 275-84		32
1450	Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 5702-5	5.6	75
1449	Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2046-52	5.6	142
1448	Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. 2002 , 54, 94-8		102
1447	Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2870-4	5.6	90
1446	Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1017-23	5.6	258
1445	Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2611-22	5.6	80
1444	Reduced ovulation rate in adolescent girls born small for gestational age. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3391-3	5.6	120
1443	Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. 2002 , 17, 1729-37		114
1442	Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 5559-65	5.6	45
1441	Molecular defects of the CYP21 gene in Spanish girls with isolated precocious pubarche. 2002 , 147, 485-8		6
1440	Amplified and orderly growth hormone secretion characterizes lean adolescents with polycystic ovary syndrome. 2002 , 147, 207-16		17
1439	Paradoxical Effect After IPL Photoepilation. 2002 , 28, 1013-1016		
1438	Comparison between buserelin and dexamethasone testing in the assessment of hirsutism. 2002 , 25, 84-90		4
1437	Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. 2002 , 77, 520-5		256
1436	Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. 2002 , 77, 674-8		30
1435	Androgen insufficiency in women: summary of critical issues. 2002 , 77 Suppl 4, S94-9		48
1434	Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. 2002 , 77, 919-27		120

1433	The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. 2002 , 77, 1136-40	33
1432	Hair loss and hirsutism in the elderly. 2002 , 18, 121-33, vii	18
1431	Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. 2002 , 17, 2858-64	281
1430	Lack of association between C-850T polymorphism of the gene encoding tumor necrosis factor-alpha and polycystic ovary syndrome. 2002 , 16, 271-4	20
1429	Hirsutism. 2002 , 12, 144-149	
1428	Tratamiento del hirsutismo con flutamida a dosis de 250 mg/d ^a : estudio clínico prospectivo a un año. 2002 , 29, 248-253	
1427	Hyperinsulinemia and uterine perfusion in patients with polycystic ovary syndrome. 2002 , 20, 276-80	8
1426	Polycystic ovary syndrome [PCOS]: comprehensive management in primary care. 2002 , 28, 208-21	
1425	Paradoxical effect after IPL photoepilation. 2002 , 28, 1013-6; discussion 1016	87
1424	Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. 2002 , 57, 343-50	193
1423	The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. 2003 , 268, 107-12	9
1422	Diagnostik des Polycystischen Ovarsyndroms. 2003 , 27, 53-59	2
1421	Gender and body hair: constructing the feminine woman. 2003 , 26, 333-344	62
1420	Antihirsutism activity of Fennel (fruits of <i>Foeniculum vulgare</i>) extract. A double-blind placebo controlled study. 2003 , 10, 455-8	42
1419	Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche. 2003 , 58, 372-9	96
1418	'Hirsutism': a psychological analysis. 2003 , 8, 327-45	74
1417	Treatment of the adolescent patient with polycystic ovary syndrome. 2003 , 30, 337-52	20
1416	Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. 2003 , 79, 942-6	50

1415	Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome. 2003 , 79, 1365-72		45
1414	Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are associated with polycystic ovary syndrome. 2003 , 79, 1353-7		23
1413	Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. 2003 , 80, 123-7		196
1412	Acne and hirsuties in teenagers. 2003 , 17, 131-48		8
1411	Gonadotropins, Gonadotropin-Releasing Hormone Tests, and the Ovary. 2003 , 356-371		
1410	Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5801-7	5.6	272
1409	Irsutismo e androgenizzazione: iter diagnostico. 2003 , 4, 108-117		
1408	Terapia farmacologica di irsutismo e androgenizzazione. 2003 , 4, 118-130		
1407	GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome. 2003 , 26, 117-22		8
1406	Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism. 2003 , 26, 206-10		5
1405	Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?. 2003 , 26, 655-9		31
1404	Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. 2003 , 52, 1627-32		44
1403	Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5887-92	5.6	88
1402	Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. 2003 , 52, 908-15		311
1401	The evaluation and management of hirsutism. 2003 , 101, 995-1007		115
1400	Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. 2003 , 67, 349-53		33
1399	Gene expression of type 2 17 beta hydroxysteroid dehydrogenase in scalp hairs of hirsute women. 2003 , 68, 641-9		18
1398	Ethnic hair update: past and present. 2003 , 48, S127-33		60

1397	Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. 2003 , 16, 33-7		98
1396	Polycystic ovary syndrome. 2003 , 16, 259-63		2
1395	Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 812-9	5.6	379
1394	[Effects of valproate on sexual development]. 2003 , 58, 443-8		1
1393	Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4682-8	5.6	189
1392	Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. 2003 , 17, 51-56		34
1391	Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment. 2003 , 17, 441-7		6
1390	Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4649-54	5.6	193
1389	Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. 2003 , 10, 390-8		205
1388	Psychological intervention in women's health: values, theory and practice. 2003 , 21, 173-182		3
1387	Diagnostik des Polycystischen Ovarsyndroms/Diagnostic Procedures in Polycystic Ovary Syndrome. 2003 , 27, 53-59		2
1386	Cyproterone acetate for hirsutism. 2003 , CD001125		38
1385	Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4116-23	5.6	159
1384	The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. 2003 , 17, 57-63		40
1383	Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2600-6	5.6	82
1382	The diagnosis and management of hirsutism. 2003 , 21, 285-93		7
1381	Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 673-9	5.6	72
1380	Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. 2003 , 18, 1210-8		113

1379	Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3333-8	5.6	147
1378	Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. 2003 , 35, 86-91		61
1377	Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4720-4	5.6	38
1376	Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2562-8	5.6	297
1375	Update: The pathogenesis and treatment of PCOS. 2003 , 28, 8-17, 22-3, table of contents; quiz 23-5		8
1374	The Evaluation and Management of Hirsutism. 2003 , 101, 995-1007		61
1373	Body morphology and its impact on adolescent and pediatric gynecology, with a special emphasis on polycystic ovary syndrome. 2003 , 15, 347-51		5
1372	Inverse relationship between density of cutaneous hair and pigmented lesion count in patients with malignant melanoma. 2003 , 13, 23-7		1
1371	Patient Education: Polycystic Ovary Syndrome. 2003 , 28, 21-23		
1370	The 5alpha-reductase type 1, but not type 2, gene is expressed in anagen hairs plucked from the vertex area of the scalp of hirsute women and normal individuals. 2003 , 36, 1447-54		10
1369	Sensibilidade, especificidade e valor preditivo dos níveis basais da 17-hidroxiprogesterona no diagnóstico da forma clássica da hiperplasia adrenal congênita por deficiência da 21-hidroxilase. 2003 , 47, 552-557		1
1368	Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. 2003 , 18, 57-60		46
1367	Safety and Adverse Effects of Androgens: How to Counsel Patients. 2004 , 79, S25-S32		29
1366	4: Polycystic ovary syndrome. 2004 , 180, 132-7		43
1365	Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4331-7	5.6	99
1364	Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4801-9	5.6	146
1363	Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2756-62	5.6	98
1362	Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3337-44	5.6	113

1361	Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4716-20	5.6	51
1360	Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3769-75	5.6	29
1359	Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2817-23	5.6	128
1358	Defective Activation of Protein Kinase C- α in Muscle by Insulin and Phosphatidylinositol-3,4,5,-(PO(4))(3) in Obesity and Polycystic Ovary Syndrome. 2004 , 2, 49-56		10
1357	Leptin and its association with polycystic ovary syndrome: a twin study. 2004 , 18, 327-34		12
1356	Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. 2004 , 9, 155-65		19
1355	Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4588-93	5.6	273
1354	Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. 2004 , 62, 283-7		25
1353	High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. 2004 , 150, 363-9		171
1352	Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. 2004 , 53, 2353-8		140
1351	An observational study of Yasmin in the management of women with polycystic ovary syndrome. 2004 , 30, 163-5		45
1350	Correlation between endocrinological parameters and acne severity in adult women. 2004 , 84, 201-4		46
1349	Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. 2004 , 21, 829-36		96
1348	Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. 2004 , 60, 241-9		170
1347	Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. 2004 , 45, 1106-15		45
1346	Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. 2004 , 18, 671-83		200
1345	The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. 2004 , 190, 1654-60		31
1344	The prevalence of androgen excess among patients with minimal unwanted hair growth. 2004 , 191, 1914-20		50

1343	Transvaginal ultrasound detection of multifollicular ovaries in non-hirsute ovulatory women. 2004 , 23, 183-7		15
1342	Testosterone and female sexuality: A skeptical view. 2004 , 1, 8-11		
1341	Serum levels of prostate-specific antigen and androgens after nasal administration of a gonadotropin releasing hormone-agonist in hirsute women. 2004 , 18, 179-85		8
1340	Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. 2004 , 19, 1725-7		35
1339	Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. 2004 , 10, 323-34		54
1338	The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 88, 703-9	5.6	51
1337	Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. 2004 , 27, 424-9		62
1336	Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism?. 2004 , 27, 61-6		1
1335	Longitudinal metabolic observation of metformin effects during pregnancy in hyperinsulinemic women with polycystic ovary syndrome: a case report. 2004 , 27, 70-5		2
1334	Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. 2004 , 27, 353-6		12
1333	Recent advances in the treatment of polycystic ovary syndrome. 2004 , 13, 1295-305		9
1332	Medical treatment regimens of hirsutism. 2004 , 8, 538-46		9
1331	The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3696-701	5.6	217
1330	Cost-effective therapy in patients with idiopathic hirsutism. 2004 , 4, 297-306		1
1329	Sertoli-Leydig cell androgens-estrogens secreting tumor of the ovary: ultra-conservative surgery. 2004 , 116, 113-6		6
1328	Personality, manual preference and neuroendocrine reactivity in hirsute subjects. 2004 , 82, 741-9		3
1327	The modern management of hirsutism. 2004 , 4, 211-220		11
1326	Pathogenesis of polycystic ovary syndrome: what is the role of obesity?. 2004 , 53, 358-76		62

1325	Relationship between body mass index and dysregulation of gonadotropins in polycystic ovary syndrome. 2004 , 1271, 30-33	
1324	Dependence of fetal hairs and sebaceous glands on fetal adrenal cortex and possible control from adrenal medulla. 2004 , 62, 486-92	12
1323	Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. 2004 , 144, 23-9	129
1322	Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. 2004 , 75, 106-11	388
1321	Increased growth hormone response to clonidine in nonobese normoinsulinemic patients with polycystic ovary syndrome. 2004 , 81, 108-13	13
1320	Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. 2004 , 81, 355-60	119
1319	A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. 2004 , 82, 421-9	225
1318	Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. 2004 , 82, 752-5	26
1317	The 121Q allele of the plasma cell membrane glycoprotein 1 gene predisposes to polycystic ovary syndrome. 2004 , 82, 743-5	13
1316	Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. 2004 , 82, 1570-9	99
1315	Polycystic ovary syndrome. 2004 , 103, 181-93	80
1314	Androgens and Mood Dysfunction in Women: Comparison of Women With Polycystic Ovarian Syndrome to Healthy Controls. 2004 , 66, 356-362	12
1313	The plasminogen activator system in young and lean women with polycystic ovary syndrome. 2004 , 51, 467-72	49
1312	Insulin Resistance and Polycystic Ovary Syndrome. 2005 , 485-509	
1311	Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. 2005 , 20, 2414-20	62
1310	Health-related quality of life issues in women with polycystic ovary syndrome. 2005 , 34, 12-20	110
1309	Biliopancreatic diversion as a novel approach to the HAIR-AN syndrome. 2005 , 15, 286-9	9
1308	Female precocious puberty, obesity and polycystic-like ovaries. 2005 , 26, 651-7	2

1307	Reproductive function and risk for PCOS in women treated for bipolar disorder. 2005 , 7, 246-59		83
1306	Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. 2005 , 30, 215-20		42
1305	Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. 2005 , 62, 683-91		33
1304	Longitudinal evaluation of reproductive function in women treated for bipolar disorder. 2005 , 89, 217-25		28
1303	Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. 2005 , 145, 72-82		83
1302	Endokrinologische Diagnostik bei Infertilität. 2005 , 38, 319-325		
1301	Body Hair Removal: The "Mundane" Production of Normative Femininity. 2005 , 52, 399-406		65
1300	Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4630-5	5.6	81
1299	Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. 2005 , 20, 258-63		55
1298	The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. 2005 , 21, 154-60		62
1297	Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. 2005 , 21, 317-23		27
1296	Associations between two single nucleotide polymorphisms in the adiponectin gene and polycystic ovary syndrome. 2005 , 21, 165-9		27
1295	Irregular cycles and steroid hormones in polycystic ovary syndrome. 2005 , 20, 2402-8		27
1294	Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3854-62	5.6	36
1293	Ovarian function during puberty in girls with type 1 diabetes mellitus: response to leuprolide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3939-45	5.6	44
1292	Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. 2005 , 37, 438-44		60
1291	High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. 2005 , 20, 2457-62		62
1290	The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. 2005 , 20, 3333-40		95

1289	A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6549-52	5.6	15
1288	Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1347-53	5.6	34
1287	Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1360-5	5.6	153
1286	Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4593-8	5.6	114
1285	Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. 2005 , 20, 894-9		53
1284	Spironolactone for hirsutism in polycystic ovary syndrome. 2005 , 39, 1517-21		21
1283	Screening for insulin resistance in women with polycystic ovarian syndrome. 2005 , 20, 84-91		4
1282	Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. 2005 , 20, 1833-6		50
1281	Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. 2005 , 20, 2396-401		48
1280	Microvascular dysfunction in women with polycystic ovary syndrome. 2005 , 20, 3219-24		33
1279	Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1644-50	5.6	50
1278	Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1651-4	5.6	19
1277	Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5711-6	5.6	195
1276	Association between ovarian volume and serum insulin levels in ovulatory patients with idiopathic hirsutism. 2005 , 83, 1561-4		9
1275	Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone. 2005 , 83, 1377-83		15
1274	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. 2005 , 83, 1565-7		8
1273	Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. 2005 , 83, 1724-8		49
1272	Serum M ^u llerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. 2005 , 84, 938-44		44

1271	Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. 2005 , 84, 798-801		42
1270	The hirsutism scoring system should be population specific. 2005 , 84, 778-80		19
1269	Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. 2005 , 38, 531-40		48
1268	Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. 2005 , 21, 206-10		20
1267	No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. 2005 , 20, 965-9		31
1266	Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1287-93	5.6	65
1265	Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. 2005 , 20, 2391-5		37
1264	Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome. 2005 , 28, 882-92		14
1263	The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. 2005 , 28, 1003-8		62
1262	Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. 2005 , 153, 853-60		255
1261	Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. 2005 , 54, 113-21		27
1260	Insulin resistance in adolescents with menstrual irregularities. 2005 , 18, 269-74		20
1259	Polycystic ovary syndrome in post-menopausal women--marker of the metabolic syndrome. 2005 , 50, 331-6		23
1258	Hirsutism. 2005 , 15, 174-182		11
1257	Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. 2005 , 122, 206-12		79
1256	Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. 2005 , 123, 204-11		41
1255	A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome. 2005 , 123, 77-81		11
1254	Prevalence of ultrasonography proved polycystic ovaries in North Indian women with type 2 diabetes mellitus. 2005 , 3, 35		17

1253	Influence of oral contraceptive pills on phenotype expression in women with polycystic ovary syndrome. 2005 , 11, 690-6		12
1252	Tratamientos coadyuvantes del hirsutismo. 2005 , 52, 365-373		
1251	Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes?. 2005 , 54, 1626-31		29
1250	Hyperpilosit [^] 'et qualit [^] 'de vie. 2005 , 132, 3-5		
1249	Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4237-45	5.6	1491
1248	Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 3451-6	5.6	113
1247	The prevalence of polycystic ovaries in Chinese women with a history of gestational diabetes mellitus. 2006 , 22, 516-20		9
1246	Mutation analysis of the WNT-4 gene in patients with polycystic ovary syndrome. 2006 , 22, 484-7		6
1245	Extensive clinical experience: nonclassical 21-hydroxylase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4205-14	5.6	238
1244	Hiperandrogenismo ov [^] f [^] ico funcional y s [^] f [^] idrome del ovario poli-qu [^] f [^] itico en la adolescencia. 2006 , 53, 34-40		1
1243	Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4361-8	5.6	103
1242	Diagnosis of hyperandrogenism: clinical criteria. 2006 , 20, 167-76		70
1241	Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. 2006 , 59, 1078-86		102
1240	Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report. 2006 , 60, 1378-81		40
1239	Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. 2006 , 55, 1582-9		32
1238	Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome. 2006 , 29, 308-12		16
1237	Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. 2006 , 85, 420-7		84
1236	Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. 2006 , 85, 996-1001		76

1235	Multifollicular ovaries in female adolescents with cystic fibrosis. 2006 , 85, 1484-7	11
1234	Dermatology of androgen-related disorders. 2006 , 24, 289-98	55
1233	Androgen insufficiency in women. 2006 , 16 Suppl A, S109-17	17
1232	Prise en charge d'une hyperandrogénie chez l'adolescente. 2006 , 21, 292-298	
1231	Women living with facial hair: the psychological and behavioral burden. 2006 , 61, 161-8	75
1230	Steroidogenic alterations and adrenal androgen excess in PCOS. 2006 , 71, 751-9	33
1229	Primary pigmented nodular adrenocortical disease associated with Carney complex: case report and literature review. 2006 , 124, 336-9	3
1228	Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. 2006 , 6, 116-21	27
1227	Determinants of emotional distress in women with polycystic ovary syndrome. 2006 , 21, 1092-9	101
1226	The adolescent gynecology patient. 2006 , 1, 49-56	
1225	Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. 2006 , 13, 37-45	67
1224	Metabolic disorders in patients with recent gestational diabetes mellitus. 2006 , 32, 408-15	9
1223	Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome. 2006 , 113, 1308-14	35
1222	Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. 2000 , 900, 245-52	39
1221	Female pattern hair loss, sebum excretion and the end-organ response to androgens. 2006 , 154, 85-9	23
1220	Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma. 2006 , 65, 396-401	11
1219	The investigation and management of the hirsute woman. 2006 , 6, 145-152	
1218	Diagnostic criteria for polycystic ovarian syndrome. 2006 , 30, 3-11	41

1217	Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism. 2006 , 274, 227-32		26
1216	Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. 2006 , 149, 532-6		25
1215	Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. 2006 , 160, 241-6		92
1214	Cardiopulmonary impairment in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2967-71	5.6	55
1213	Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. 2006 , 21, 121-8		47
1212	Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 3970-80	5.6	171
1211	Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. 2006 , 21, 451-6		26
1210	Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. 2006 , 114, 182-7		18
1209	Comparison of clinical, ultrasonographic, and biochemical differences at the beginning of puberty in healthy girls born either small for gestational age or appropriate for gestational age: preliminary results. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 3377-81	5.6	35
1208	Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 3878-84	5.6	61
1207	Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2295-302	5.6	62
1206	Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. 2006 , 21, 1400-7		68
1205	Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1309-16	5.6	102
1204	Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome. 2006 , 154, 883-90		18
1203	Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1345-50	5.6	145
1202	Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome. 2006 , 155, 859-65		26
1201	Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 946-52	5.6	90
1200	Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. 2006 , 22, 336-42		38

1199	Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome?. 2006 , 22, 324-8		19
1198	Association between Circulating Tumor Necrosis Factor-Alpha, Interleukin-6, and Insulin Resistance in Normal-Weight Women with Polycystic Ovary Syndrome. 2006 , 4, 122-8		66
1197	Granulosa cell aromatase enzyme activity: effects of follicular fluid from patients with polycystic ovary syndrome, using aromatase conversion and [11C]vorozole-binding assays. 2006 , 22, 685-91		11
1196	Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4842-8	5.6	194
1195	Polycystic ovary syndrome in bulimic women--an evaluation based on the new diagnostic criteria. 2006 , 22, 388-94		41
1194	Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. 2006 , 19, 831-42		38
1193	Criteria for oral glucose tolerance testing of obese minority youth. 2007 , 20, 703-9		3
1192	Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 2007 , 157, 669-76		76
1191	Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 456-61	5.6	118
1190	Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. 2007 , 30, 471-8		114
1189	Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 705-13	5.6	220
1188	Does eflornithine help women face hirsutism?. 2007 , 45, 62-4		
1187	Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. 2007 , 14, 2799-812		38
1186	Ultrasound in polycystic ovary syndrome--the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. 2007 , 22, 2501-8		47
1185	Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3498-503	5.6	66
1184	Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3128-35	5.6	62
1183	17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4208-17	5.6	39
1182	Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1710-4	5.6	44

1181	Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 110-6	5.6	129
1180	Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3285-91	5.6	10
1179	Polycystic ovaries after precocious pubarche: relation to prenatal growth. 2007 , 22, 395-400		67
1178	Update on drugs for hyperactivity in childhood. 2007 , 45, 37-40		
1177	Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1347-52	5.6	41
1176	Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria. 2007 , 23, 153-60		43
1175	Ovarian reserve in women with polycystic ovary syndrome who underwent laparoscopic ovarian drilling. 2007 , 23, 455-60		36
1174	Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. 2007 , 157, 771-8		30
1173	Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype. 2007 , 157, 661-8		12
1172	Assessment of insulin resistance in the idiopathic hirsutism. 2007 , 63, 126-31		16
1171	Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. 2007 , 157, 195-200		38
1170	Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2066-73	5.6	35
1169	Endocrinological markers for assessment of hyperandrogenemia in hirsute women. 2007 , 67, 35-41		16
1168	Acceleration of luteinizing hormone pulse frequency in adolescent girls with a history of central precocious puberty with versus without hyperandrogenism. 2007 , 68, 278-85		9
1167	Diagnosis of polycystic ovary syndrome. 2007 , 50, 168-77		66
1166	Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. 2007 , 133, 191-6		42
1165	Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. 2007 , 134, 196-201		127
1164	Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. 2007 , 87, 1363-8		38

1163	Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin. 2007 , 88, 125-30		21
1162	Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. 2007 , 88, 131-8		26
1161	Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate-resistant polycystic ovary syndrome. 2007 , 88, 418-24		16
1160	The Dehydroepiandrosterone And WellNess (DAWN) study: research design and methods. 2007 , 28, 153-68		20
1159	Lack of association between common polymorphisms in the 17beta-hydroxysteroid dehydrogenase type V gene (HSD17B5) and precocious pubarche. 2007 , 105, 176-80		15
1158	Polycystic ovary syndrome. 2007 , 370, 685-97		998
1157	Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3446-52	5.6	62
1156	Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1379-84	5.6	136
1155	CAPN10 UCSNP-43, UCSNP-19 and UCSNP-63 polymorphisms and metabolic syndrome in polycystic ovary syndrome. 2007 , 23, 173-8		21
1154	Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. 2007 , 23, 231-7		25
1153	Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. 2007 , 23, 273-8		18
1152	A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. 2007 , 10, 335-43		56
1151	Therapeutic options in the polycystic ovary syndrome. 2007 , 27, 123-9		14
1150	Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. 2007 , 56, 992-7		49
1149	Polycystic Ovarian Syndrome. 2007 , 65-75		
1148	Ovarian hilus-cell hyperplasia and high serum testosterone in a patient with postmenopausal virilization. 2007 , 13, 472-5		5
1147	Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. 2007 , 51, 972-9		28
1146	Color Doppler sonographic analysis of uterine and ovarian artery blood flow in women with polycystic ovary syndrome. 2007 , 35, 305-13		34

1145	The progesterone receptor PROGINS polymorphism is not related to oxidative stress factors in women with polycystic ovary syndrome. 2007 , 6, 29	10
1144	Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?. 2007 , 33, 166-73	15
1143	Men with Kennedy disease have a reduced risk of androgenetic alopecia. 2007 , 157, 290-4	40
1142	Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. 2007 , 67, 129-34	54
1141	Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. 2007 , 67, 557-62	6
1140	The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. 2007 , 67, 811-5	39
1139	Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. 2007 , 67, 735-42	119
1138	Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. 2007 , 67, 917-22	53
1137	Assessment of androgens in women with adult-onset acne. 2007 , 46, 1188-91	40
1136	Endocrine effects of valproate in adolescent girls with epilepsy. 2007 , 48, 470-7	48
1135	Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. 2007 , 48, 1366-70	48
1134	Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. 2007 , 48, 1371-7	33
1133	Hirsutism. 2008 , 62, 433-43	32
1132	Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. 2007 , 32, 548-54	44
1131	Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. 2007 , 73, 188-193	38
1130	Correlation between finger-prick and venous ciclosporin levels: association with gingival overgrowth and hypertrichosis. 2007 , 22, 2111-8	7
1129	The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. 2008 , 277, 25-30	20
1128	Androgenisierungserscheinungen in den Wechseljahren. 2008 , 41, 894-901	1

1127	The prevalence of eating disorders in women with facial hirsutism: an epidemiological cohort study. 2008 , 41, 427-31		27
1126	Management of polycystic ovarian syndrome. 2008 , 13, 14-19		
1125	Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. 2008 , 49, 2069-77		29
1124	The clinical evaluation of hirsutism. 2008 , 21, 376-91		40
1123	Can adiponectin predict abnormal glucose tolerance in Thai women with polycystic ovary syndrome?. 2008 , 34, 55-61		5
1122	A systematic review of commonly used medical treatments for hirsutism in women. 2008 , 68, 800-5		59
1121	Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. 2008 , 68, 976-81		35
1120	Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). 2008 , 69, 792-8		68
1119	Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review. 2008 , 69, 831-44		19
1118	PCOS, sexuality, and clitoral vascularisation: a pilot study. 2008 , 5, 2886-94		43
1117	Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary syndrome. 2008 , 57, 999-1004		43
1116	LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo/amenorrhoea. 2008 , 16, 765-71		21
1115	Treatment of hirsutism with myo-inositol: a prospective clinical study. 2008 , 17, 579-82		40
1114	CYP1A1 gene polymorphism and polycystic ovary syndrome. 2008 , 16, 356-60		16
1113	Comparison of metabolic effects of metformin and rosiglitazone in the management of polycystic ovary syndrome (PCOS): A prospective, parallel, randomized, open-label study. 2008 , 2, 37-46		5
1112	Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1105-20	5.6	263
1111	Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. 2008 , 23, 642-50		157
1110	Hair Growth and Disorders. 2008 ,		27

1109	Polymorphisms of the endothelial nitric oxide synthase gene in premenopausal women with polycystic ovary syndrome. 2008 , 61, 256-9	8
1108	Assessment of Hirsutism and Acne in Oligomenorrheic or Amenorrheic Adolescents. 2008 , 21, 79-80	
1107	Robinow Syndrome and Lower Vaginal Agenesis: Management of an Unusual Genital Anomaly. 2008 , 21, 80-81	
1106	Assessment of Oligomenorrhea and Secondary Amenorrhea in Adolescents. 2008 , 21, 88-89	
1105	Surgical Planning in Patients with Cloacal Anomalies and Obstructed Gynecological Systems: The Scrambled Renal-Genital System Association and Radiological Clues. 2008 , 21, 89-90	
1104	Polycystic ovarian disease unmasked by pulsatile GnRH therapy in a subgroup of women with hypothalamic amenorrhea. 2008 , 89, 404-9	19
1103	Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. 2008 , 89, 625-34	69
1102	Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. 2008 , 89, 649-55	57
1101	Androgen receptor gene (CAG)n polymorphism in patients with polycystic ovary syndrome. 2008 , 90, 860-3	27
1100	Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. 2008 , 90, 2310-7	23
1099	Androgen receptor gene CAG repeat polymorphism in women with polycystic ovary syndrome. 2008 , 90, 2318-23	40
1098	Prostate-specific antigen in the serum of women with benign breast disease. 2008 , 138, 212-6	21
1097	Polycystic ovary syndrome in perimenarchal obese adolescents: experience with magnetic resonance imaging. 2008 , 18, S8-S13	1
1096	The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. 2008 , 69, 52-60	32
1095	Treatment of hirsutism with combined pill containing drospirenone. 2008 , 24, 220-3	15
1094	Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. 2008 , 65, 233-9	45
1093	Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. 2008 , 24, 669-73	35
1092	Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1153-60	5.6 111

1091	Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. 2008 , 23, 2564-9		31
1090	Lipid and lipoprotein profile in women with polycystic ovary syndrome. 2008 , 86, 199-204		40
1089	Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. 2008 , 158, 517-23		26
1088	Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. 2008 , 23, 2127-33		37
1087	Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. 2008 , 111, 385-95		40
1086	Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. 2008 , 24, 718-23		25
1085	Exercise and body image distress in overweight and obese women with polycystic ovary syndrome: a pilot investigation. 2008 , 24, 555-61		29
1084	Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age 2008, 21, 973-84		9
1083	A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. 2008 , 168, 321-8		107
1082	How effective are pharmacologic treatments for women with hirsutism?. 2008 , 4, 538-9		
1081	Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: a randomized, controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3900-6	5.6	44
1080	Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?. 2008 , 294, E576-81		151
1079	Hair and Scalp Diseases. 2008 ,		6
1078	Ovarian stimulation in obese and non-obese polycystic ovary syndrome using a low-dose step-up regimen with two different starting doses of recombinant follicle-stimulating hormone. 2008 , 36, 1197-204		5
1077	Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. 2008 , 148, 569-77		111
1076	Polycystic Ovary Syndrome. 2008 , 165-174		1
1075	Hirsutism in a Fifty-Eight-Year-Old Woman. 2008 , 18, 216-218		
1074	Idiopathic hirsutism: excessive bodily and facial hair in women. 2008 , 17, 192-7		7

1073	3alpha-Hydroxysteroid dehydrogenase type III deficiency: a novel mechanism for hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1298-303	5.6	7
1072	Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. 2008 , 23, 1602-6		50
1071	Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. 2008 , 23, 2113-21		63
1070	Meibomian gland alterations in polycystic ovary syndrome. 2008 , 33, 133-8		14
1069	Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. 2008 , 30, 671-679		82
1068	Insulin sensitivity does not differentiate by hirsutism in non-obese women with polycystic ovary syndrome. 2008 , 55, 465-8		4
1067	Ovarian hyperthecosis in the context of an adrenal incidentaloma in a postmenopausal woman. 2008 , 52, 1184-8		10
1066	Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. 2010 , 1, 85-95		3
1065	Virilizing ovarian steroid cell tumor in a 40 year old South Indian female: a case report. 2009 , 2, 7521		6
1064	Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. 2009 , 25, 199-204		19
1063	Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. 2009 , 22, 815-26		5
1062	Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. 2009 , 15, 477-88		232
1061	A favorable metabolic and antiatherogenic profile in carriers of CYP21A2 gene mutations supports the theory of a survival advantage in this population. 2009 , 72, 337-43		4
1060	Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3602-10	5.6	19
1059	Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4938-45	5.6	74
1058	Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. 2009 , 218, 231-6		13
1057	Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. 2009 , 24, 1726-31		85
1056	Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. 2009 , 88, 32-45		69

1055	Androgen replacement therapy in Turner syndrome: a pilot study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4820-7	5.6	51
1054	Rationelle Diagnostik in der gyn^kologischen Endokrinologie und Reproduktionsmedizin âTeil 1: Physiologie und Symptomabkl^rung. 2009 , 69, R43-R65		
1053	Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1182-90	5.6	39
1052	"It is always on my mind": women's experiences of their bodies when living with hirsutism. 2009 , 30, 358-72		34
1051	Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4961-70	5.6	84
1050	Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. 2009 , 297, R387-95		115
1049	The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3714-20	5.6	113
1048	Elevated coagulation and inflammatory markers in adolescents with a history of premature adrenarche. 2009 , 58, 576-81		14
1047	A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. 2009 , 6, 2579-90		39
1046	Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. 2009 , 6, 3376-84		23
1045	Intense pulsed light photoepilation in hirsute women: the role of obesity. 2009 , 24, 415-8		4
1044	Ver^nderungen an Haut und Haaren bei internistischen Erkrankungen. 2009 , 7, 9-16		
1043	Einfluss von HRT auf Haut und Haare. 2009 , 7, 253-262		
1042	Interobserver variability of modified Ferriman-Gallwey hirsutism score in a Turkish population. 2009 , 279, 473-9		35
1041	Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. 2009 , 280, 559-63		148
1040	Polycysteus ovariumsyndroom. 2009 , 77, 159-164		
1039	Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome. 2009 , 35, 123-9		8
1038	Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis. 2009 , 2, 5		9

1037	Assessment of ultrasonographic features of polycystic ovaries is associated with modest levels of inter-observer agreement. 2009 , 2, 6	23
1036	BioCycle study: design of the longitudinal study of the oxidative stress and hormone variation during the menstrual cycle. 2009 , 23, 171-84	108
1035	Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. 2009 , 33, 1249-56	23
1034	Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. 2009 , 63, 160-9	23
1033	Hirsutism in young women. 2009 , 11, 101-107	2
1032	Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. 2009 , 32, 13-7	9
1031	Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy. 2009 , 32, 821-4	2
1030	Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. 2009 , 32, 210-8	23
1029	Menstrual disorders in adolescent females: current concepts. 2009 , 55, 45-113	6
1028	Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. 2009 , 91, 2537-44	32
1027	Cardiovascular risk in normal weight, eumenorrheic, nonhirsute daughters of patients with polycystic ovary syndrome: a pilot study. 2009 , 92, 240-9	19
1026	Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. 2009 , 92, 635-42	42
1025	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. 2009 , 91, 456-88	1268
1024	The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome. 2009 , 92, 660-6	19
1023	Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. 2009 , 92, 1372-1377	42
1022	Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. 2009 , 19, 797-804	31
1021	The Editor's Workshop: Pediatric and adolescent gynecology: What's the issue? What's the answer? What's the big picture? What's the national perspective?. 2009 , 22, 195-6	
1020	Effect of body mass index on clinical manifestations in patients with polycystic ovary syndrome. 2009 , 107, 54-7	16

1019	Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. 2009 , 58, 586-93		35
1018	Diagnosis and Management of Polycystic Ovary Syndrome. 2009 ,		0
1017	Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1570-8	5.6	141
1016	Serum visfatin in Asian women with polycystic ovary syndrome. 2009 , 25, 536-42		23
1015	Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. 2009 , 25, 427-34		30
1014	Hirsutism. 2009 , 25, 140-8		13
1013	Obesity and insulin resistance associated with lower plasma vitamin B12 in PCOS. 2009 , 19, 721-6		34
1012	Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. 2009 , 105, 32-5		9
1011	Hirsutismo y trastornos menstruales en la adolescencia. 2009 , 7, 144-151		
1010	Diagnóstico del Síndrome de Ovario Poliquístico: nuevos fenotipos, nuevas incógnitas. 2009 , 137,		1
1009	A novel association between polycystic ovary syndrome and Helicobacter pylori. 2009 , 338, 174-7		17
1008	Polycystic ovary syndrome and prolactinoma association. 2009 , 48, 611-3		7
1007	Polycystic ovary syndrome. 2009 , 14, 86-95		7
1006	Adolescent gynecology. 2009 , 113, 935-947		27
1005	Polycystic Ovary Syndrome in Adolescents. 2010 , 6, 108-122		
1004	Examen gynecológico. 2010 , 5, 1-26		2
1003	The management of female hirsutism with the anti-androgen agent cyproterone. 1985 , 11, 233-40		1
1002	Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. 2010 , 25, 204-11		40

1001	Hyperandrogenic et hirsutisme. 2010 , 7, 1-8	1
1000	Development of morphologically dominant follicles is associated with fewer metabolic disturbances in amenorrheic women with polycystic ovary syndrome: a pilot study. 2010 , 36, 759-66	8
999	A study on clinical and sonographic features in obese and nonobese patients with polycystic ovary syndrome. 2010 , 281, 467-71	5
998	High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. 2010 , 281, 1009-14	26
997	Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. 2010 , 282, 691-4	8
996	Methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish patients with polycystic ovary syndrome. 2010 , 38, 127-33	22
995	Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency. 2010 , 38, 260-5	20
994	Exploración ginecológica. 2010 , 46, 1-27	
993	Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. 2010 , 202, 577.e1-8	26
992	PCOS and urethrovaginal space: 3-D volumetric and vascular analysis. 2010 , 7, 2755-64	11
991	Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes. 2010 , 3, 23	39
990	Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. 2010 , 24, 186-8	52
989	Uterine blood flow in pregnant patients with polycystic ovary syndrome: relationships with clinical outcomes. 2010 , 117, 711-21	41
988	Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. 1995 , 132, 936-41	21
987	Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. 2010 , 73, 732-8	47
986	Interventional studies for polycystic ovarian syndrome in children and adolescents. 2010 , 4, 59-73	9
985	A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. 2010 , 33, 1544-8	23
984	Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. 2010 , 4, 359-64	41

983	GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. 2010 , 163, 55-62		39
982	High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. 2010 , 162, 1117-22		40
981	Polycystic ovary syndrome in adolescence. 2010 , 1205, 175-84		11
980	Treatment of Hirsutism in a Woman With Familial Partial Lipodystrophy of Dunnigan Type. 2010 , 20, 290-292		
979	Long-Term Gynecological Outcomes in Women with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. 2010 , 2010, 784297		3
978	Hirsutism: investigation and management. 2010 , 5, 189-195		3
977	The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 109-17	5.6	90
976	L-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study. 2010 , 26, 861-8		7
975	High prevalence of polycystic ovary syndrome in women born small for gestational age. 2010 , 25, 2124-31		70
974	Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. 2010 , 118, 161-6		35
973	Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. 2010 , 118, 291-7		21
972	Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. 2010 , 25, 2783-91		65
971	Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. 2010 , 25, 1005-13		44
970	Medical Treatment of Hirsutism in Women. 2010 , 17, 2530-8		14
969	Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 810-9	5.6	92
968	Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. 2010 , 25, 450-6		122
967	Menstrual irregularity: a possible clinical marker of metabolic dysfunction in women with class III obesity. 2010 , 26, 768-72		9
966	Textbook of Cosmetic Dermatology. 2010 ,		11

965	Endothelial function in young women with polycystic ovary syndrome (PCOS): Implications of body mass index (BMI) and insulin resistance. 2010 , 4, e1-e82	8
964	Diagnosis and management of hirsutism. 2010 , 1205, 166-74	34
963	Digit ratios by computer-assisted analysis confirm lack of anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. 2010 , 8, 156	19
962	Adiponectin and resistin concentrations after glucose load in adolescents with polycystic ovary syndrome. 2010 , 26, 30-8	5
961	Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome. 2010 , 33, 446-50	2
960	Spermatogenesis in Klinefelter syndrome. 2010 , 33, 789-93	46
959	Psychological well-being and sexarche in women with polycystic ovary syndrome. 2010 , 25, 1497-503	68
958	Visually scoring hirsutism. 2010 , 16, 51-64	198
957	Assessment of diagnostic competence of plasmatic androgens on polycystic ovary syndrome based on receiver operator characteristic curves. 2010 , 26, 600-6	8
956	Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome. 2010 , 46, 474-81	36
955	Characteristics of polycystic ovarian syndrome and relationship with ghrelin in adolescents. 2010 , 23, 285-9	13
954	Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. 2010 , 82, 131-8	20
953	Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. 2010 , 82, 139-46	73
952	Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. 2010 , 149, 31-6	36
951	Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. 2010 , 93, 1200-7	43
950	Serologic markers of autoimmunity in women with polycystic ovary syndrome. 2010 , 93, 2291-4	43
949	Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. 2010 , 93, 2303-10	39
948	Increased secretion of amylin in women with polycystic ovary syndrome. 2010 , 94, 211-5	3

947	The insulin-resistant phenotype of polycystic ovary syndrome. 2010 , 94, 1052-8	28
946	Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. 2010 , 94, 1417-1425	47
945	Relationship between interleukin-6 levels and ambulatory blood pressure in women with polycystic ovary syndrome. 2010 , 94, 1437-1443	10
944	Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. 2010 , 94, 2208-13	47
943	Steroid profiles in ovarian follicular fluid in women with and without polycystic ovary syndrome, analyzed by liquid chromatography-tandem mass spectrometry. 2010 , 94, 2228-33	37
942	Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms. 2010 , 94, 2800-3.e1	10
941	Manejo de la patologí a suprarrenal en Atenci³n Primaria. 2010 , 36, 140-149	0
940	Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. 2010 , 20, 492-8	22
939	Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. 2010 , 21, 572-80	30
938	Grid analysis improves reliability in follicle counts made by ultrasonography in women with polycystic ovary syndrome. 2010 , 36, 712-8	24
937	Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. 2010 , 17, 767-75	4
936	Comprehensive clinical management of hirsutism. 2010 , 26, 484-93	43
935	Disorders of Hair. 2010 , 1-100	26
934	Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. 2010 , 26, 348-55	24
933	The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome. 2010 , 26, 673-83	12
932	Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact?. 2010 , 26, 698-703	18
931	Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. 2011 , 27, 814-9	29
930	Managing the reproductive health of pediatric and adolescent patients. 2011 , 6, 655-666	2

929	Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. 2011 , 26, 1469-77	101
928	Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. 2011 , 34, 97-100	28
927	Successful white hair removal with combined coloring and intense pulsed Light (IPL): a randomized clinical trial. 2011 , 29, 773-9	11
926	The Boston IVF Handbook of Infertility. 2011 ,	4
925	Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study. 2011 , 27, 925-30	30
924	Association of subclinical hypothyroidism and phenotype, insulin resistance, and lipid parameters in young women with polycystic ovary syndrome. 2011 , 95, 2039-43	39
923	Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. 2011 , 95, 2044-9	50
922	Defining hirsutism in Chinese women: a cross-sectional study. 2011 , 96, 792-6	80
921	Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. 2011 , 96, 1043-7	31
920	Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism?. 2011 , 96, 1266-70.e1	35
919	Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. 2011 , 96, 1275-80	31
918	The phenotype of polycystic ovary syndrome ameliorates with aging. 2011 , 96, 1259-65	84
917	Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index. 2011 , 96, 1497-1502.e1	13
916	Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women. 2011 , 154, 167-71	28
915	Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome. 2011 , 157, 180-4	3
914	Polycystic ovary syndrome and increased polyp numbers as risk factors for malignant transformation of endometrial polyps in premenopausal women. 2011 , 112, 200-3	18
913	Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. 2011 , 24, 161-5	46
912	Homocysteine and ghrelin link with polcystic ovary syndrome in relation to obesity. 2011 , 24, 211-7	9

911	Alterations of folliculogenesis in women with polycystic ovary syndrome. 2011 , 124, 58-64	28
910	A comparison of polycystic ovary syndrome and related factors between lesbian and heterosexual women. 2011 , 21, 191-8	13
909	CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome. 2011 , 76, 1383-8	10
908	Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. 2011 , 31, 97-103	27
907	Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome. 2011 , 27, 579-86	17
906	Efficacy and safety of the selective 11 β HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. 2011 , 5, 166-76	67
905	The Hirsute woman: challenges in evaluation and management. 2011 , 17, 807-18	20
904	[Metabolic abnormalities in polycystic ovary syndrome women: obese and non obese]. 2011 , 33, 310-6	1
903	Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman. 2011 , 2011,	5
902	A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. 2011 , 55, 590-8	18
901	Fact or myth? Pain reduction in solvent-assisted removal of adhesive tape. 2011 , 20, 380-3	2
900	Effects of an 11 β hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. 2011 , 13, 498-504	115
899	Increased arterial stiffness in mildly-hypertensive women with polycystic ovary syndrome. 2011 , 37, 402-11	22
898	Evaluation of carotid wall thickness and vertebro-basilar system insufficiency in patients with obese polycystic ovary syndrome. 2011 , 37, 997-1003	6
897	Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. 2011 , 37, 1229-37	5
896	Physiological changes in scalp, facial and body hair after the menopause: a cross-sectional population-based study of subjective changes. 2011 , 164, 508-13	15
895	Effects of hyperlipidaemia on glucocorticoid metabolism: results of a randomized controlled trial in healthy young women. 2011 , 74, 551-7	3
894	How should postmenopausal androgen excess be evaluated?. 2011 , 75, 160-4	42

893	Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. 2011 , 75, 698-703		33
892	Characterizing the composition of underarm and forearm skin using confocal raman spectroscopy. 2011 , 33, 257-62		10
891	Ultrasonographic extended-view technique for evaluation of abdominal fat distribution in lean women with polycystic ovary syndrome. 2011 , 90, 600-8		17
890	Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. 2011 , 43, 55-9		462
889	Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. 2011 , 36, 1470-9		42
888	Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS. 2011 , 8, 84		24
887	Ovarian morphology and endocrine function in polycystic ovary syndrome. 2011 , 284, 1443-8		17
886	Kosmetische Therapie des Hirsutismus. 2011 , 9, 117-120		1
885	Androgenproduzierende Tumoren. 2011 , 9, 109-116		1
884	Androgenisierungserscheinungen an der Haut. 2011 , 44, 43-53		1
883	The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. 2011 , 2, 153-161		232
882	Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3493-501	5.6	80
881	Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1827-34	5.6	72
880	The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E821-4	5.6	15
879	The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. 2011 , 27, 920-4		44
878	Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women. 2011 , 9, 375-80		19
877	Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. 2011 , 164, 53-60		60
876	Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation. 2011 , 26, 423-30		13

875	Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. 2011 , 26, 214-20		45
874	The oligomenorrhic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. 2011 , 26, 1486-94		72
873	Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. 2011 , 27, 491-5		26
872	The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. 2011 , 18, 1230-6		27
871	Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. 2011 , 26, 202-13		97
870	Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3533-40	5.6	109
869	Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the southeastern region of Turkey. 2011 , 39, 1529-35		5
868	Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. 2011 , 43, 723-7		18
867	The promoter variant -803 G>A in the RBP4 gene is not associated with BMI, metabolic parameters or blood pressure in Caucasian children. 2011 , 119, 628-32		6
866	Climacteric Commentaries. 2011 , 14, 505-512		1
865	A study on the clinical and hormonal profile of patients with hirsutism. 2012 , 3, 88-91		2
864	MTHFR C677T polymorphism is associated with hyperlipidemia in women with polycystic ovary syndrome. 2012 , 5, 52-6		23
863	Association of polycystic ovary syndrome and Graves' disease: Is autoimmunity the link between the two diseases. 2012 , 16, 982-6		12
862	Pattern of urinary albumin excretion in normotensive young and adolescent Indian women with polycystic ovary syndrome. 2012 , 16, 277-82		7
861	High prevalence of hirsutism and menstrual disorders in obese adolescent girls and adolescent girls with type 1 diabetes mellitus despite different hormonal profiles. 2012 , 166, 307-16		20
860	Decidual endovascular trophoblast invasion in women with polycystic ovary syndrome: an experimental case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2441-9	5.6	62
859	Benefits of pedometer-measured habitual physical activity in healthy women. 2012 , 37, 149-56		13
858	Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. 2012 , 27, 1481-8		31

857	Family-based analysis of susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. 2012 , 27, 294-8	39
856	Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?. 2012 , 27, 2494-502	89
855	Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. 2012 , 27, 2082-8	52
854	Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. 2012 , 18, 638-51	124
853	Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. 2012 , 25, 459-66	22
852	Period problems: disorders of menstruation in adolescents. 2012 , 97, 554-60	31
851	Leptin-to-adiponectin, adiponectin-to-leptin ratios, and insulin are specific and sensitive markers associated with polycystic ovary syndrome: a case-control study from Bahrain. 2012 , 10, 98-102	10
850	A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. 2012 , 28, 723-30	45
849	Increased frequency of the DI genotype of the angiotensin-I converting enzyme and association of the II genotype with insulin resistance in polycystic ovary syndrome. 2012 , 166, 695-702	13
848	Hirsutism: A Clinico-investigative Study. 2012 , 4, 246-50	8
847	Clinico-investigative Profile of Patients of Hirsutism in a Tertiary Level Institution. 2012 , 4, 69-74	8
846	Virilizing leydig-sertoli cell ovarian tumor associated with endometrioid carcinoma of the endometrium in a postmenopausal patient: case report and general considerations. 2012 , 5, 149-53	6
845	The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome. 2012 , 3,	2
844	Role of the CAG repeat polymorphism of the androgen receptor gene in polycystic ovary syndrome (PCOS). 2012 , 120, 73-9	40
843	Is there an interaction between polycystic ovary syndrome and gingival inflammation?. 2012 , 83, 1529-37	37
842	Infertilit� s f� minines d�brigine endocrinienne. 2012 , 7, 1-26	
841	Two- and three-dimensional sonographic and color Doppler techniques for diagnosis of polycystic ovary syndrome. The stromal/ovarian volume ratio as a new diagnostic criterion. 2012 , 31, 1015-24	28
840	Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. 2012 , 31, 476-80	62

839	Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system. 2012 , 163, 165-9	25
838	Subclinical inflammation in obese women with polycystic ovary syndrome. 2012 , 17, 195-202	2
837	Allelic variants of insulin receptor substrate-1 gene in Egyptian women with polycystic ovary syndrome. 2012 , 21, 1689-1696	1
836	Androgenisierung. 2012 , 10, 265-280	1
835	CD4(+)CD28(null) T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes. 2012 , 98, 1609-15	15
834	Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. 2012 , 98, 1627-34	25
833	Study of Association between Polycystic Ovary Syndrome and Dietary Intake. 2012 , 23, 29-40	1
832	Infertilidad femenina de origen endocrino. 2012 , 48, 1-28	
831	Ferriman-Gallwey scores, serum androgen and mullerian inhibiting substance levels in hirstute adolescent girls. 2012 , 25, 300-4	2
830	The influence of obesity on androstenedione to testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia. 2012 , 28, 249-52	12
829	Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. 2012 , 28, 264-8	6
828	Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. 2012 , 10, 273-9	7
827	Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. 2012 , 27, 3067-73	359
826	An approach to the patient with hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2957-68	5.6 29
825	The investigation and management of hirsutism. 2012 , 38, 182-6	15
824	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 2012 , 18, 146-70	281
823	CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels. 2012 , 128, 107-12	35
822	Metabolic manifestations of polycystic ovary syndrome in nonobese adolescents: retinol-binding protein 4 and ectopic fat deposition. 2012 , 97, 1009-15	10

821	Adipose expression of adipocytokines in women with polycystic ovary syndrome. 2012 , 98, 235-41	47
820	Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. 2012 , 98, 1047-52	24
819	The relationship between LH and thyroid volume in patients with PCOS. 2012 , 5, 43	9
818	The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. 2012 , 28, 365-9	3
817	Polycystic ovary syndrome in patients with epilepsy: a study in 102 Chinese women. 2012 , 21, 729-33	17
816	Neopterin: a promising marker for the inflammation in polycystic ovary syndrome. 2012 , 28, 879-83	6
815	Hormones sexuelles. 2012 , 19-33	
814	Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. 2012 , 29, 763-74	27
813	A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?. 2012 , 286, 1065-71	27
812	IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. 2012 , 286, 763-9	13
811	Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women. 2012 , 74, 136-42	7
810	17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities. 2012 , 28, 606-10	6
809	Acne vulgaris in women: prevalence across the life span. 2012 , 21, 223-30	70
808	Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. 2012 , 10, 96	23
807	Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients. 2012 , 5, 45	10
806	Insulin resistance in women with hirsutism. 2012 , 8, 342-6	15
805	Androgens and hair: a biological paradox with clinical consequences. 154-176	4
804	Sequelae of doping with anabolic steroids. 535-546	1

803	Psycho-Social and Sexual Well-Being in Women with Polycystic Ovary Syndrome. 2012,	1
802	Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain. 2012, 4, 201-6	8
801	Hiperandrogenismo: pubarquia precoz y s ^í ndrome de ovario poliqu ^í stico. Etiolog ^í a y posibilidades terap ^é uticas. 2012, 14, 61-67	
800	[Frequency and risk factors for metabolic syndrome in adolescents and adults women with polycystic ovary syndrome]. 2012, 34, 357-61	4
799	S-plasty for pilonidal disease: modified primary closure reducing tension. 2012, 82, 63-9	9
798	Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?. 2012, 40, 223-9	52
797	^Bergewicht, Hirsutismus und tiefe Stimme bei einer Jugendlichen. 2012, 160, 211-214	
796	Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. 2012, 26, 1364-71	17
795	Increased prevalence of diabetes and polycystic ovary syndrome in women with a history of preterm birth: a case-control study. 2012, 119, 266-75	13
794	Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. 2012, 25, 391-400	17
793	Menstrual irregularity and poly cystic ovarian syndrome among adolescent girls--a 2 year follow-up study. 2012, 79 Suppl 1, S69-73	22
792	Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome. 2012, 285, 767-70	10
791	2D and 3D Ultrasound Examination of Labia Minora. 2013, 42, 153-160	1
790	Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes. 2013, 100, 1081-8	44
789	Polycystic ovary syndrome and the differential diagnosis of hyperandrogenism. 2013, 15, 171-176	15
788	Serum calcitonin gene-related peptide levels in women with polycystic ovary syndrome. 2013, 287, 1235-9	1
787	Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study. 2013, 287, 525-31	50
786	Evaluating reported candidate gene associations with polycystic ovary syndrome. 2013, 99, 1774-8	17

785	Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome. 2013 , 168, 178-82	12
784	Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. 2013 , 28, 1919-28	24
783	Predictive factors of health-related quality of life in patients with polycystic ovary syndrome: a structural equation modeling approach. 2013 , 100, 1389-96	18
782	Hyperandrogenic women treated with a continuous-regimen oral contraceptive. 2013 , 171, 307-10	10
781	Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism. 2013 , 226, 291-5	34
780	Increased prolidase activity and oxidative stress in PCOS. 2013 , 79, 105-10	45
779	Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: a case control study. 2013 , 11, 77	10
778	Psychological investigation in patients with polycystic ovary syndrome. 2013 , 11, 141	31
777	Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study. 2013 , 100, 214-8	22
776	An isocaloric low glycemic index diet improves insulin sensitivity in women with polycystic ovary syndrome. 2013 , 113, 1523-1531	36
775	Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. 2013 , 8, e200-e204	11
774	Nonclassic congenital adrenal hyperplasia and the heterozygote carrier. 2013 , 8, 239-246	1
773	Body imaging and sexual behavior in lean women with polycystic ovary syndrome. 2013 , 10, 2752-60	21
772	Morning plasma cortisol is low among obese women with polycystic ovary syndrome. 2013 , 29, 1045-7	8
771	Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. 2013 , 20, 1508-17	15
770	Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. 2013 , 29, 483-7	7
769	Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome. 2013 , 29, 1036-9	14
768	Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1575-82	5.6 15

767	Is interleukin-17 involved in the interaction between polycystic ovary syndrome and gingival inflammation?. 2013 , 84, 1827-37	33
766	Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. 2013 , 99, 936-42	17
765	Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. 2013 , 14, 335-45	240
764	Adiponectin, leptin and ghrelin levels in obese adolescent girls with polycystic ovary syndrome. 2013 , 26, 27-30	17
763	Testosterone secretion in elite adolescent swimmers does not modify bone mass acquisition: a 1-year follow-up study. 2013 , 99, 270-278	8
762	Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. 2013 , 99, 1786-90	8
761	Subclinical hypothyroidism in young women with polycystic ovary syndrome: an analysis of clinical, hormonal, and metabolic parameters. 2013 , 99, 588-92	48
760	What is the best approach to the teenage patient presenting with nonclassical congenital adrenal hyperplasia: should we always treat with glucocorticoids?. 2013 , 78, 338-41	13
759	Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome. 2013 , 78, 52-9	44
758	PCOS: perspectives from a pediatric endocrinologist and a pediatric gynecologist. 2013 , 43, 104-13	3
757	Evaluation and treatment of hirsutism. 2013 , 10, 138-145	
756	How to recognize PCOS: results of a web-based survey at IVF-worldwide.com. 2013 , 26, 500-5	9
755	Metformin treatment in different phenotypes of polycystic ovary syndrome. 2013 , 288, 1131-6	4
754	Prevalence of polycystic ovary syndrome in women in China: a large community-based study. 2013 , 28, 2562-9	223
753	Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. 2013 , 13, 115-123	2
752	Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. 2013 , 28, 538-44	76
751	Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. 2013 , 36, 636-41	19
750	Impact of angiotensin II type 1 receptor gene polymorphism on insulin resistance in polycystic ovary syndrome. 2013 , 121, 188-93	2

749	Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. 2013 , 17, 304-9	45
748	CYP21A2 genotypes do not predict the severity of hyperandrogenic manifestations in the nonclassical form of congenital adrenal hyperplasia. 2013 , 45, 301-7	15
747	Management of hirsutism. 2013 , 17, S77-82	4
746	Functioning adrenocortical tumors in children-secretory behavior. 2013 , 5, 27-32	9
745	Health-related quality of life, depression and anxiety correlate with the degree of hirsutism. 2013 , 227, 278-84	39
744	Evaluation of only the chin or lower abdomen for predicting hirsutism. 2013 , 17, 896-8	5
743	No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours. 2013 , 78, 533-8	12
742	PON1-108 TT and PON1-192 RR genotypes are more frequently encountered in Greek PCOS than non-PCOS women, and are associated with hyperandrogenaemia. 2013 , 79, 259-66	15
741	Síndrome de ovario poliquístico. diagnóstico y manejo. 2013 , 24, 818-826	
740	Polycystic ovary syndrome and obesity do not affect vascular parameters related to early atherosclerosis in young women without glucose metabolism disturbances, arterial hypertension and severe abnormalities of lipid profile. 2013 , 29, 370-4	14
739	Glucose metabolism in obese and lean adolescents with polycystic ovary syndrome. 2013 , 26, 319-24	5
738	Accelerated early pubertal progression, ovarian morphology, and ovarian function in prospectively followed low birth weight (LBW) girls. 2013 , 26, 223-30	10
737	Polycystic Ovary Syndrome and Hepatic Steatosis: Could Low-Grade Chronic Inflammation Be Mediated by the Spleen?. 2013 , 11, 179-191	3
736	Androgenisierung. 2013 , 5, 30-41	
735	Epidemiology, diagnosis, and management of polycystic ovary syndrome. 2013 , 6, 1-13	670
734	[Metabolic profile in women of different body mass indices with polycystic ovary syndrome]. 2013 , 35, 413-20	2
733	Evaluación clínica del pelo corporal en una población de mujeres colombianas: determinación del punto de corte para el diagnóstico de hirsutismo. 2013 , 33,	
732	A Combined Treatment with Myo-Inositol and Monacolin K Improve the Androgen and Lipid Profiles of Insulin-Resistant PCOS Patients. 2013 , 02,	1

731	The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). 2014 , 15, 70-83		13
730	Ultrasonography in Gynecology. 31-42		
729	Insulin dynamics in young women with polycystic ovary syndrome and normal glucose tolerance across categories of body mass index. 2014 , 9, e92995		20
728	Polycystic Ovary Syndrome: Features, Diagnostic Criteria and Treatments. 2014 , 03,		2
727	Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). 2014 , 13, 213-21		21
726	The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. 2015 , 14, 109-17		5
725	Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. 2014 , 27, 1175-9		22
724	Increased androgen, anti-Müllerian hormone, and sporadic anovulation in healthy, eumenorrheic women: a mild PCOS-like phenotype?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2208-16 ^{5,6}		24
723	Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. 2014 , 12, 88		26
722	Androgenisierungserscheinungen an der weiblichen Haut. 2014 , 30, 20-28		
721	Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3418-26	5.6	73
720	Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome. 2014 , 74, 465-9		13
719	Comparative evaluation of sonographic ovarian morphology of Indian women with polycystic ovary syndrome versus those of normal women. 2014 , 18, 180-4		1
718	A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. 2014 , 18, 317-24		64
717	Testosterone- and cortisol-secreting adrenocortical oncocytoma: an unusual cause of hirsutism. 2014 , 2014, 206890		9
716	Lower cocaine- and amphetamine-regulated transcript levels pose a risk for developing PCOS. 2014 , 46, 702-6		1
715	Association of Pro12Ala polymorphism with insulin sensitivity and body mass index in patients with polycystic ovary syndrome. 2014 , 2, 199-206		19
714	Endocrine check-up in adolescents and indications for referral: A guide for health care providers. 2014 , 18, S26-38		5

713	Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations. 2014 , 18, S72-9	7
712	Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome. 2014 , 3, 120-6	24
711	Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen?. 2014 , 45, 226-33	7
710	Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome. 2014 , 29, 518-24	12
709	Sexual orientations of women with polycystic ovary syndrome: clinical observation in Taiwan. 2014 , 53, 542-6	9
708	Diabetes, ovarian tumor, hyperparathyroidism, and papillary cancer: A chance association?. 2014 , 61, 548-550	
707	Diabetes, ovarian tumor, hyperparathyroidism, and papillary cancer: association by chance?. 2014 , 61, 548-50	
706	Health-related quality of life in patients with polycystic ovary syndrome (PCOS): a model-based study of predictive factors. 2014 , 11, 1023-1032	35
705	Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls. 2014 , 16, 37-47	9
704	Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. 2014 , 81, 621-8	20
703	Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. 2014 , 15, 1547-53	26
702	Oxandrolone for the treatment of bone marrow failure in Fanconi anemia. 2014 , 61, 11-9	20
701	Polycystic ovary syndrome in Iranian adolescents. 2014 , 26, 559-65	12
700	Social support: an important factor for quality of life in women with hirsutism. 2014 , 12, 183	13
699	Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. 2014 , 21, 952-61	21
698	Insulin-like growth factor 1, liver enzymes, and insulin resistance in patients with PCOS and hirsutism. 2014 , 44, 781-6	8
697	The impact of obesity on clinical, metabolic and hormonal features in patients with polycystic ovary syndrome. 2014 , 5,	
696	Diagnostic evaluation of patients presenting with hirsutism. 2014 , 5,	

695	Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. 2014 , 7, 31		17
694	Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. 2014 , 21, 612-23		60
693	Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study. 2014 , 27, 161-5		22
692	Association between circulating adiponectin levels and polycystic ovarian syndrome. 2014 , 7, 18		31
691	Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. 2014 , 81, 426-31		28
690	No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 203-11	5.6	13
689	Gonadal dysfunction in morbidly obese adolescent girls. 2014 , 101, 1142-8		10
688	Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Hair Loss. 2014 , 223-242		1
687	Polycystic Ovary Syndrome. 2014 ,		1
686	Short- and long-term clinical skin effects of testosterone treatment in trans men. 2014 , 11, 222-9		81
685	Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. 2014 , 11, 1999-2011		150
684	Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial. 2014 , 11, 831-9		27
683	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. 2014 , 81, 408-17		78
682	Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism. 2014 , 15, 305-17		11
681	Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer. 2014 , 90, 94-100		24
680	Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome. 2014 , 21, 1034-1043		55
679	Hyperinsulinaemic androgen excess in adolescent girls. 2014 , 10, 499-508		33
678	Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis. 2014 , 181, 124-9		5

677	Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study. 2014 , 29, 2339-51	39
676	Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. 2014 , 102, 826-30	25
675	Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. 2014 , 29, 1773-9	26
674	17-Hydroxyprogesterone in children, adolescents and adults. 2014 , 51, 424-40	27
673	LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response. 2014 , 40, 224-8	5
672	Assessment of insulin resistance in lean women with polycystic ovary syndrome. 2014 , 102, 250-256.e3	30
671	Validation of a simplified method to assess hirsutism in the Iranian population. 2014 , 174, 91-5	15
670	The effects of adipocytokines on the endocrino-metabolic features and obstetric outcome in pregnant obese women with polycystic ovary syndrome. 2014 , 19, 293-302	8
669	Evidence-Based Treatment of Hirsutism. 2014 , 498-503	
668	Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. 2014 , 58, 182-7	40
667	Reproductive endocrinology and infertility. 187-189	
666	Irregular bleeding in a 25-year-old woman. 207-210	
665	Quality of Life and Body Mass Index in Overweight Adult Women with Polycystic Ovary Syndrome During a Lifestyle Modification Program. 2015 , 44, 587-99	8
664	Diagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls. 2015 , 44, e223-30	7
663	Benefits of short-term structured exercise in non-overweight women with polycystic ovary syndrome: a prospective randomized controlled study. 2015 , 27, 2293-7	17
662	A Clinical Approach to Endocrine & Metabolic Diseases. 2015 ,	
661	Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome. 2015 , 11, 3941-7	16
660	Preparation and clinical evaluation of Finastride gel in the treatment of idiopathic Hirsutism. 2015 , 4, 12-8	2

659	Valutazione e monitoraggio dell'irsutismo con metodi obiettivi: difficoltà e prospettive. 2015 , 16, 110-115	
658	Hirsutism: managing the basics. 1-10	
657	History and physical examination of polycystic ovary syndrome: Detecting too much or too little. 161-179	
656	Pseudofolliculitis barbae in women: a clinical perspective. 2015 , 173, 279-81	8
655	GLUT4 translocation is not impaired after acute exercise in skeletal muscle of women with obesity and polycystic ovary syndrome. 2015 , 23, 2207-15	11
654	Fructose content of low calorie diets: effect on cardiometabolic risk factors in obese women with polycystic ovarian syndrome: a randomized controlled trial. 2015 , 4, 144-54	14
653	Genetic polymorphism of CYP1A1 (T6235C) Gene as a Risk Factor for Polycystic Ovary Syndrome. 2015 , 05,	2
652	Low Starch/Low Dairy Diet Results in Successful Treatment of Obesity and Co-Morbidities Linked to Polycystic Ovary Syndrome (PCOS). 2015 , 5,	8
651	EVALUATION OF PARA- AND PERIRENAL FAT THICKNESS AND ITS ASSOCIATION WITH METABOLIC DISORDERS IN POLYCYSTIC OVARY SYNDROME. 2015 , 21, 878-86	6
650	Impact of a Lifestyle Modification Program on Menstrual Irregularity among Overweight or Obese Women with Polycystic Ovarian Syndrome. 2015 , 21, 161	1
649	Complementary Therapies for Idiopathic Hirsutism: Topical Licorice as Promising Option. 2015 , 2015, 659041	2
648	Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours. 2015 , 2015,	8
647	Prevalence of glucose tolerance test abnormalities in women with polycystic ovarian syndrome. 2015 , 1739-1745	2
646	Effect of Dietary Weight Loss on Menstrual Regularity in Obese Young Adult Women with Polycystic Ovary Syndrome. 2015 , 28, 457-61	34
645	A simplified questionnaire for self-assessment of hirsutism in population-based studies. 2015 , 172, 451-9	1
644	Androgen Receptor CAG Repeat Length in Relation to Phenotype Among Females with Nonclassical 21-Hydroxylase Deficiency. 2015 , 47, 491-6	6
643	Tamoxifen-associated hirsutism: an unusual side effect in a 5-year-old girl with McCune-Albright syndrome. 2015 , 28, 1191-3	0
642	Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact. 2015 , 84, 355-60	20

641	Hyperandrogen^ ĩnie âDiagnostik und Therapiekonzepte. 2015 , 48, 891-902	2
640	Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients. 2015 , 29, 42-7	15
639	Serum HLA-G levels in women with polycystic ovary syndrome. 2015 , 31, 243-6	3
638	Ultrasound features of polycystic ovaries relate to degree of reproductive and metabolic disturbance in polycystic ovary syndrome. 2015 , 103, 787-94	23
637	Sexual and relational satisfaction in couples where the woman has polycystic ovary syndrome: a dyadic analysis. 2015 , 30, 625-31	9
636	Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. 2015 , 94, 494-500	15
635	Adrenal androgen excess and body mass index in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 942-50	5.6 39
634	Endocrine evaluation of hirsutism. 2015 , 1, 90-94	4
633	Atherogenic dyslipidemia, subclinical atherosclerosis, non-alcoholic fatty liver disease and insulin resistance in polycystic ovarian syndrome / [Polikistik over sendromunda ins^ ĩn direnci, aterojenik dislipidemi, subklinik aterosklerozis ve non-alkolik ya ĩ ĩkaraci ĩr hastal ĩ ĩ]. 2015 , 40, 24-30	3
632	Mood disorders and quality of life in polycystic ovary syndrome. 2015 , 31, 431-4	33
631	Evaluation of affective temperament and anxiety-depression levels of patients with polycystic ovary syndrome. 2015 , 185, 214-8	27
630	The Diagnosis of Polycystic Ovary Syndrome during Adolescence. 2015 ,	161
629	Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. 2015 , 172, 627-38	83
628	Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. 2015 , 191, 101-5	3
627	Evidence-based approach to cutaneous hyperandrogenism in women. 2015 , 73, 672-90	31
626	LC-MS/MS improves screening towards 21-hydroxylase deficiency. 2015 , 31, 296-300	7
625	Optimal management of polycystic ovary syndrome in adolescence. 2015 , 100, 1076-83	13
624	Women self-perception of excess hair growth, as a predictor of clinical hirsutism: a population-based study. 2015 , 38, 923-8	3

623	Insulin resistance and cardiometabolic risk factors in obese children and adolescents: a hierarchical approach. 2015 , 28, 589-96	11
622	An association study between USP34 and polycystic ovary syndrome. 2015 , 8, 30	4
621	Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. 2015 , 189, 19-23	23
620	MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. 2015 , 173, R47-58	115
619	A comprehensive approach in diagnosing the polycystic ovary syndrome. 2015 , 11, 501-12	8
618	Atypical polycystic ovary syndrome--a genetic analysis. 2015 , 123, 55-60	
617	Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. 2015 , 94, 204-11	26
616	Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. 2015 , 38, 1319-26	46
615	Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index. 2015 , 104, 467-73	7
614	The Diagnosis of Polycystic Ovary Syndrome in Adolescents. 2015 , 136, 1154-65	115
613	Association between red blood cell distribution width and polycystic ovary syndrome. 2015 , 40, 181-7	6
612	PCOS in adolescence and type 2 diabetes. 2015 , 15, 564	24
611	Women with polycystic ovary syndrome have greater muscle strength irrespective of body composition. 2015 , 31, 237-42	21
610	The effect of prolactin levels on MPV in women with PCOS. 2015 , 82, 747-52	5
609	Polycystic ovarian syndrome. 2015 , 99, 221-35	49
608	Plasma Visfatin Levels in Adolescents with Polycystic Ovary Syndrome: A Prospective Case-Control Study. 2015 , 28, 249-53	6
607	Differential Contributions of Polycystic Ovary Syndrome (PCOS) Manifestations to Psychological Symptoms. 2015 , 42, 383-94	10
606	The effect of chromium supplementation on polycystic ovary syndrome in adolescents. 2015 , 28, 114-8	23

605	Diagnostic characteristics and metabolic risk factors of cases with polycystic ovary syndrome during adolescence. 2015 , 28, 78-83	13
604	The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. 2015 , 291, 451-5	42
603	Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. 2015 , 172, 79-88	23
602	Physiology and Pathology of the Female Reproductive Axis. 2016 , 589-663	3
601	Physiology and Disorders of Puberty. 2016 , 1074-1218	20
600	Subclinical Hypothyroidism in PCOS: Impact on Presentation, Insulin Resistance, and Cardiovascular Risk. 2016 , 2016, 2067087	26
599	Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. 2016 , 14, 5401-5407	8
598	Metabolic syndrome in infertile women with polycystic ovarian syndrome. 2016 , 60, 199-204	11
597	Does AMH Reflect Follicle Number Similarly in Women with and without PCOS?. 2016 , 11, e0146739	17
596	Poly Cystic Ovarian Syndrome: An Updated Overview. 2016 , 7, 124	108
595	Perioperative hair removal in the 21st century: Utilizing an innovative vacuum-assisted technology to safely expedite hair removal before surgery. 2016 , 44, 1639-1644	7
594	Association between left ventricular mass, androgens, adiposity and insulin resistance in girls with precocious pubarche: a case-control study. 2016 , 84, 394-401	3
593	The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. 2016 , 84, 23-9	21
592	Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women. 2016 , 32, 723-727	2
591	Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome?. 2016 , 37, 46-55	27
590	Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency. 2016 , 29, 571-8	
589	Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. 2016 , 157, 77-90	39
588	A European Network for the Investigation of Gender Incongruence: Endocrine Part. 2016 , 13, 994-9	69

587	Increased risk of humerus and lower leg fractures in postmenopausal women with self-reported premenopausal hirsutism and/or oligomenorrhea. 2016 , 203, 162-6		4
586	Relationship between polycystic ovary syndrome and ancestry in European Americans. 2016 , 106, 1772-1777		5
585	Obesity may be the common pathway for sleep-disordered breathing in women with polycystic ovary syndrome. 2016 , 24, 32-39		10
584	The evaluation of endothelial function and structure in hirsute patients in reproductive age. 2016 , 206, 208-212		4
583	Correlations between impulsiveness and biochemical parameters in women with polycystic ovary syndrome. 2016 , 207, 5-10		2
582	Role of Folliculo-luteal Function in Human Reproduction. 2016 ,		1
581	Das polyzystische Ovarsyndrom im Jugendalter. 2016 , 49, 830-837		1
580	Steroid Metabolomic Disease Signature of Nonsyndromic Childhood Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4329-4337	5.6	20
579	Fertility-related quality of life from two RCT cohorts with infertility: unexplained infertility and polycystic ovary syndrome. 2016 , 31, 2268-79		25
578	The link between metabolic features and TSH levels in polycystic ovary syndrome is modulated by the body weight: an euglycaemic-hyperinsulinaemic clamp study. 2016 , 175, 433-41		15
577	Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. 2016 , 175, 551-560		10
576	Helicobacter pylori infection and polycystic ovary syndrome in adolescent and young adult patients. 2016 , 42, 1768-1772		1
575	Increased adiponin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. 2016 , 85, 910-917		27
574	Genetic, hormonal and metabolic aspects of PCOS: an update. 2016 , 14, 38		167
573	Risk factors in adolescence for the development of polycystic ovary syndrome. 2016 , 49, 838-846		1
572	Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. 2016 , 4, CD001750		112
571	Suboptimal dietary intake is associated with cardiometabolic risk factors in women with polycystic ovary syndrome. 2016 , 73, 177-183		3
570	Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial. 2016 , 85, 764-771		39

569	Association between anti-Mullerian hormone and insulin resistance in non-obese adolescent females with polycystic ovary syndrome. 2016 , 32, 926-930	8
568	Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial. 2016 , 42, 279-85	22
567	Hirsutism region and the likelihood of metabolic syndrome: is there a link?. 2016 , 53, 607-9	0
566	Impact of hypovitaminosis D on clinical, hormonal and insulin sensitivity parameters in normal body mass index polycystic ovary syndrome women. 2016 , 36, 508-12	9
565	Stein and Leventhal: 80 years on. 2016 , 214, 247.e1-247.e11	40
564	Prevalence and possible mechanisms of reactive hypoglycemia in polycystic ovary syndrome. 2016 , 31, 1105-12	9
563	Observation of phenotypic variation among Indian women with polycystic ovary syndrome (PCOS) from Delhi and Srinagar. 2016 , 32, 566-70	13
562	Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. 2016 , 53, 271-9	39
561	Sonographic markers of ovarian morphology, but not hirsutism indices, predict serum total testosterone in women with regular menstrual cycles. 2016 , 105, 1322-1329.e1	6
560	Body Mass Index below Obesity Threshold Implies Similar Cardiovascular Risk among Various Polycystic Ovary Syndrome Phenotypes. 2016 , 25, 61-6	7
559	Assessing new terminal body and facial hair growth during pregnancy: toward developing a simplified visual scoring system for hirsutism. 2016 , 105, 494-500	5
558	Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome: Associations With Quality of Life and Depression. 2016 , 152, 783-8	35
557	A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. 2016 , 39, 747-54	23
556	Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome. 2016 , 152, 391-8	44
555	A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. 2016 , 10, S95-8	9
554	Polycystic ovary syndrome is associated with increased osteopontin levels. 2016 , 174, 415-23	8
553	The Role of Anti-M ^u llerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. 2016 , 23, 655-61	18
552	Metabolic syndrome in Greek women with polycystic ovary syndrome: prevalence, characteristics and associations with body mass index. A prospective controlled study. 2016 , 293, 915-23	17

551	Issues Faced by Women With Hirsutism: State of the Science. 2016 , 37, 636-45	3
550	Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. 2016 , 53, 538-42	24
549	NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in polycystic ovary syndrome. 2016 , 32, 46-50	7
548	Oral glucose tolerance test significantly impacts the prevalence of abnormal glucose tolerance among Indian women with polycystic ovary syndrome: lessons from a large database of two tertiary care centers on the Indian subcontinent. 2016 , 105, 194-201.e1-3	15
547	Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. 2016 , 32, 147-50	17
546	Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. 2016 , 32, 218-22	9
545	Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. 2016 , 32, 42-5	8
544	Testosterone concentrations in female athletes and ballet dancers with menstrual disorders. 2016 , 16, 490-7	20
543	Body Image in Young Gender Dysphoric Adults: A European Multi-Center Study. 2016 , 45, 559-74	68
542	Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome. 2017 , 55, 625-634	8
541	Hyperandrogenism in a postmenopausal woman: a rare case of ectopic adrenal cortical gland. 2017 , 33, 185-187	3
540	Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. 2017 , 33, 1545-1557	23
539	Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. 2017 , 86, 725-730	19
538	Pelvic floor dysfunction and polycystic ovary syndrome. 2017 , 20, 262-267	5
537	Single-nucleotide polymorphism of INS, INSR, IRS1, IRS2, PPAR-G and CAPN10 genes in the pathogenesis of polycystic ovary syndrome. 2017 , 96, 87-96	15
536	Practical Approach to the PCOS Patient. 2017 , 6, 11-20	
535	Metabolic Outcomes, Bone Health, and Risk of Polycystic Ovary Syndrome in Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogues. 2017 , 87, 162-169	14
534	Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. 2017 , 217, 191.e1-191.e19	15

533	Polycystic ovary syndrome is associated with anogenital distance, a marker of prenatal androgen exposure. 2017 , 32, 937-943	39
532	Hyperandrogenism in adolescent girls: relationship with the somatotrophic axis. 2017 , 30, 561-568	3
531	Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. 2017 , 33, 698-701	17
530	High Prevalence of Polycystic Ovary Syndrome in Type 1 Diabetes Mellitus Adolescents: Is There a Difference Depending on the NIH and Rotterdam Criteria?. 2017 , 87, 333-341	9
529	The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. 2017 , 22, 172-182	9
528	Assessment of the body composition of patients with polycystic ovary syndrome using dual-energy X-ray absorptiometry. 2017 , 136, 285-289	4
527	Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. 2017 , 42, 145-153	14
526	Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years. 2017 , 35, 331-339	4
525	Effect of Non-Surgical Periodontal Therapy Along With Myo-Inositol on High-Sensitivity C-Reactive Protein and Insulin Resistance in Women With Polycystic Ovary Syndrome and Chronic Periodontitis: A Randomized Controlled Trial. 2017 , 88, 999-1011	15
524	High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. 2017 , 32, 1075-1091	201
523	Hyperhomocysteinemia, insulin resistance and body mass index in Iranian young women with polycystic ovary syndrome. 2017 , 22, 149-155	4
522	Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome. 2017 , 3, 37-43	28
521	Endocrine evaluation of hirsutism. 2017 , 3, S6-S10	17
520	Skin Manifestations of Insulin Resistance: From a Biochemical Stance to a Clinical Diagnosis and Management. 2017 , 7, 37-51	21
519	High salivary testosterone-to-androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome. 2017 , 86, 567-575	12
518	Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers. 2017 , 77, 1573-1582	6
517	No. 350-Hirsutism: Evaluation and Treatment. 2017 , 39, 1054-1068	4
516	Elevated circulating levels of xenopsin-related peptide-1 are associated with polycystic ovary syndrome. 2017 , 296, 841-846	2

515	Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. 2017 , 32, 2315-2323	38
514	Depression and Anxiety in Polycystic Ovary Syndrome: Etiology and Treatment. 2017 , 19, 83	50
513	Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. 2017 , 7, 5339	28
512	Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. 2017 , 46, 579-585	7
511	Can serum vaspin levels predict clomiphene resistance in infertile women with PCOS?. 2017 , 217, 6-11	5
510	Polycystic ovary morphology: age-based ultrasound criteria. 2017 , 108, 548-553	14
509	An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. 2017 , 88, 371-395	166
508	The relationship of urocortin-2 with insulin resistance patients having PCOS. 2017 , 33, 124-127	5
507	Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. 2017 , 33, 119-123	14
506	Association of Prooxidant-Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI. 2017 , 32, 315-322	4
505	Efficacy of acupuncture on menstrual frequency in women with polycystic ovary syndrome: Protocol for a randomized, controlled trial. 2017 , 96, e8828	4
504	Polycystic ovary syndrome: Pelvic MRI as alternative to pelvic ultrasound for the diagnosis in overweight and obese adolescent girls. 2017 , 4, 147-152	2
503	N 350-Hirsutisme : ^ valuation et traitement. 2017 , 39, 1069-1084	
502	Polycystic Ovary Syndrome. 111-118	2
501	COMPARISON OF FINASTERIDE, METFORMIN, AND FINASTERIDE PLUS METFORMIN IN PCOS. 2017 , 13, 84-89	3
500	PCOS in adolescence: effect of metformin on menstrual irregularities. 2017 , 6, 3490	
499	The Contribution of New Areas to the Total Hirsutism Scores in Basrah Hirsute Women. 2017 , 5,	3
498	Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study. 2017 , 12, e0173695	13

497	Evolution of metabolic alterations 5 Years after early puberty in a cohort of girls predisposed to polycystic ovary syndrome. 2017 , 15, 56		4
496	Assessment of the relationship between serum vitamin (A, B 12 , C, D, folate) and zinc levels and polycystic ovary syndrome. 2017 , 2, 62-69		4
495	Precocious Puberty. 2018 , 589-615		2
494	Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1258-1264	5.6	28
493	Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1233-1257	5.6	123
492	Tight interplay in early pregnancy between follistatin and anti-mullerian hormone in women with polycystic ovarian syndrome (PCOS). 2018 , 297, 1307-1316		2
491	Diagnostic Evaluation, Comorbidity Screening, and Treatment of Polycystic Ovary Syndrome in Adolescents in 3 Specialty Clinics. 2018 , 31, 367-371		8
490	Relationship of Polycystic Ovarian Syndrome with Cardiovascular Risk Factors. 2018 , 12, 375-380		12
489	Association between polycystic ovary syndrome and hot flash presentation during the midlife period. 2018 , 25, 691-696		5
488	Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estroprogestinic treatment. 2018 , 34, 704-708		16
487	Vom Symptom zur Diagnose und Therapie. 2018 , 69-180		
486	Diagnostic Criteria for PCOS. 2018 , 11-21		
485	Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center. 2018 , 60, 167-174		6
484	Understanding and Addressing Hair Disorders in Transgender Individuals. 2018 , 19, 517-527		24
483	New perspectives on the definition and management of polycystic ovary syndrome. 2018 , 41, 1123-1135		35
482	Do Different Diagnostic Criteria Impact Polycystic Ovary Syndrome Diagnosis for Adolescents?. 2018 , 31, 258-262		11
481	What is adolescent polycystic ovary syndrome?. 2018 , 54, 351-355		9
480	A diagnostic curiosity of isolated androstenedione elevation due to autoantibodies against horseradish peroxidase label of the immunoassay. 2018 , 476, 103-106		3

479	The Value of Prostate-Specific Antigen in Diagnosis of Polycystic Ovarian Syndrome in Adolescent Girls. 2018 , 31, 263-269	2
478	The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome. 2018 , 16, 34	29
477	[Diffuse hypertrichosis revealing non-classical congenital adrenal hyperplasia]. 2018 , 145, 270-277	1
476	The Diagnostic Value of Anti-M ^u llerian Hormone in Early Post Menarche Adolescent Girls with Polycystic Ovarian Syndrome. 2018 , 31, 362-366	3
475	Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. 2018 , 6, 455-464	7
474	Can AMH levels predict the need for increased medication during IVF/ICSI in PCOS women?. 2018 , 31, 32-38	4
473	Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. 2018 , 25, 269-275	36
472	Polycystic Ovary Syndrome among Obese Adolescents. 2018 , 34, 45-48	9
471	Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16-29 years. 2018 , 58, 222-233	17
470	Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. 2018 , 34, 238-242	7
469	Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome. 2018 , 38, 236-240	5
468	Good Practice in Pediatric and Adolescent Gynecology. 2018 ,	2
467	Very low dose of flutamide in the treatment of hyperandrogenism. 2018 , 34, 394-398	4
466	Family-based analysis of GGT1 and HNF1A gene polymorphisms in patients with polycystic ovary syndrome. 2018 , 36, 115-119	2
465	Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study. 2018 , 139, 20-27	17
464	Diagnosis of Polycystic Ovarian Syndrome in Adolescence. 2018 , 143-159	1
463	Polycystic ovarian syndrome. 2018 , 117-129	
462	Major determinants of circulating myostatin in polycystic ovary syndrome. 2019 , 17, 1383-1389	2

461	Polycystic Ovary Syndrome in Bipolar Affective Disorder: A Hospital-based Study. 2018 , 40, 121-128	5
460	Serum Preptin and Amylin Levels with Respect to Body Mass Index in Polycystic Ovary Syndrome Patients. 2018 , 24, 7517-7523	1
459	The Relationship between Vitamin D Status and the Menstrual Cycle in Young Women: A Preliminary Study. 2018 , 10,	9
458	Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications. 2018 ,	1
457	Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. 2018 , 14, e1007813	166
456	Disorders of the Scalp and Hair. 2018 , 385-397	
455	Polycystic ovary syndrome and its impact on Iranian women's quality of life: a population-based study. 2018 , 18, 164	16
454	Assessment of anogenital distance as a diagnostic tool in polycystic ovary syndrome. 2018 , 37, 741-749	11
453	The association of hs-CRP and fibrinogen with anthropometric and lipid parameters in non-obese adolescent girls with polycystic ovary syndrome. 2018 , 31, 1213-1220	5
452	Human umbilical cord blood mesenchymal stem cells engineered to overexpress growth factors accelerate outcomes in hair growth. 2018 , 22, 555-566	10
451	Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. 2018 , 34, 1073-1080	14
450	Association between Insulin Resistance and Cardiovascular Risk Factors in Polycystic Ovary Syndrome Patients. 2018 , 40, 188-195	10
449	New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men. 2018 , 86, 71-125	10
448	Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome. 2018 , 37, 367-374	4
447	The effect of CAG repeats length on differences in hirsutism among healthy Israeli women of different ethnicities. 2018 , 13, e0195046	2
446	Polycystic Ovary Syndrome and Hyperandrogenic States. 2019 , 520-555.e13	2
445	Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. 2019 , 42, 303-312	5
444	Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. 2019 , 3, 1545-1573	110

443	Polyzystisches Ovarsyndrom (PCOS). 2019 , 1-12	
442	Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index). 2019 , 91, 544-552	12
441	Changes in diet composition with urbanization and its effect on the polycystic ovarian syndrome phenotype in a Western Indian population. 2019 , 112, 758-763	5
440	Polycystic Ovary Syndrome. 2019 , 55-67	0
439	FP728LOW LEAN TISSUE AND HIGH FAT TISSUE INDEX ARE ASSOCIATED WITH DECREASED QUALITY OF LIFE IN DIALYSIS PATIENTS. 2019 , 34,	
438	Polyzystisches Ovar-Syndrom (PCOS). 2019 , 12, 170-173	1
437	Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences. 2019 , 45, 2330-2337	17
436	Determination of insulin resistance and its relationship with hyperandrogenemia,anti-M ^u llerian hormone, inhibin A, inhibin B, and insulin-like peptide-3 levels in adolescent girls with polycystic ovary syndrome. 2019 , 49, 1117-1125	2
435	Continuous versus intermittent aerobic exercise in the improvement of quality of life for women with polycystic ovary syndrome: A randomized controlled trial. 2021 , 26, 1307-1317	6
434	Endocrinology of Hirsutism: From Androgens to Androgen Excess Disorders. 2019 , 53, 108-119	7
433	Besonderheiten des Haarwuchses und -verlustes in der Pubertät. 2019 , 167, 1142-1148	
432	Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). 2019 , 11,	77
431	Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome. 2019 , 19, 2220-2230	5
430	Insulin resistance is associated with hirsutism in unselected reproductive-aged women. 2019 , 90, 586-591	3
429	Cross-sectional study of the prevalence of polycystic ovary syndrome in rural and urban populations. 2019 , 146, 370-379	5
428	Sexual Function and Socio-Sexual Difficulties in Women with Polycystic Ovary Syndrome (PCOS). 2019 , 79, 498-509	7
427	Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. 2019 , 65, 175-183	5
426	Association between circulating neuregulin 4 levels and metabolic, atherogenic, and AMH profile of polycystic ovary syndrome. 2019 , 39, 975-980	6

425	Lasers for Hair Removal. 2019 , 273-287	1
424	Androgens in women: Androgen-mediated skin disease and patient evaluation. 2019 , 80, 1497-1506	28
423	Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): A case-control study. 2019 , 13, 1957-1961	13
422	Are there differences in basal thrombophilias and C-reactive protein between women with or without PCOS?. 2019 , 38, 1018-1026	3
421	Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version. 2019 , 59, 1015-1025	2
420	Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. 2019 , 12, 25	15
419	Polycystic ovary syndrome in adult women. 2019 , 152, 450-457	5
418	Dietary intake and lifestyle behaviour in different phenotypes of polycystic ovarian syndrome: a case-control study. 2019 , 32, 413-421	7
417	Molecular Mechanisms in Skeletal Muscle Underlying Insulin Resistance in Women Who Are Lean With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1841-1854 ^{5,6}	30
416	No correlation between serum testosterone levels and state-level anger intensity in transgender people: Results from the European Network for the Investigation of Gender Incongruence. 2019 , 110, 29-39	14
415	Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. 2019 , 20,	22
414	Investigation and management of subfertility. 2019 , 72, 579-587	18
413	Contemporary Management of Polycystic Ovarian Syndrome. 2019 , 62, 271-281	2
412	MiRNAs Regulating Insulin Sensitivity Are Dysregulated in Polycystic Ovary Syndrome (PCOS) Ovaries and Are Associated With Markers of Inflammation and Insulin Sensitivity. 2019 , 10, 879	18
411	The diagnosis and treatment of PCOS in adolescents: an update. 2019 , 31, 562-569	26
410	Jugendliche mit polyzystischem Ovarialsyndrom?. 2019 , 1	
409	Polycystic ovary syndrome in adult women. 2019 , 152, 450-457	14
408	Anthropometric indices to predict insulin resistance in women with polycystic ovary syndrome in China. 2019 , 38, 101-107	1

407	Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. 2019 , 46, 455-459	12
406	Dietary intake, body composition and metabolic parameters in women with polycystic ovary syndrome. 2019 , 38, 2342-2348	5
405	Circulating neuregulin-1 levels in polycystic ovary syndrome. 2019 , 39, 504-509	3
404	Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. 2019 , 35, 220-223	42
403	Pregnancy outcomes, fertility, and family planning in women with psoriatic arthritis. 2020 , 13, 70-75	5
402	Decreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndrome. 2020 , 36, 222-225	4
401	Aesthetic Applications of Intense Pulsed Light. 2020 ,	1
400	The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study. 2020 , 24, 1027-1034	10
399	The prevalence of heterozygous CYP21A2 deficiency in patients with idiopathic acne, hirsutism, or both. 2020 , 67, 665-672	4
398	Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study. 2020 , 36, 61-65	16
397	Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome. 2020 , 43, 305-313	3
396	Polycystic Ovarian Syndrome in Adolescents: Early Diagnosis and Intervention. 2020 , 34, 166-170	
395	Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. 2020 , 113, 197-204	10
394	Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial. 2020 , 24,	2
393	Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome. 2020 , 36, 496-500	5
392	Hiperandrogenismo femenino. 2020 , 13, 1007-1018	
391	Protocolo diagnóstico del hirsutismo. 2020 , 13, 1029-1032	0
390	Comparison of metabolic syndrome elements in White and Asian women with polycystic ovary syndrome: results of a regional, American cross-sectional study. 2020 , 1, 305-313	

- 389 Characteristics of Adolescents with Differing Polycystic Ovary Syndrome Phenotypes. **2020**, 33, 697-702
- 388 Das polyzystische Ovarsyndrom: Aktuelle Evidenz und praktische Empfehlungen. **2020**, 15, 37-47
- 387 Controversies in the diagnosis of polycystic ovary syndrome. **2020**, 14, 2633494120913032 6
- 386 The impact of irritable bowel syndrome on health-related quality of life in women with polycystic ovary syndrome. **2020**, 18, 226 4
- 385 Health-related quality of life in women with polycystic ovary syndrome attending to a tertiary hospital in Southeastern Spain: a case-control study. **2020**, 18, 232 3
- 384 Haarwuchs und -verlust in der Pubertät. **2020**, 12, 34-41
- 383 Cognitive testing of a survey instrument for self-assessed menstrual cycle characteristics and androgen excess. **2020**, 6, 19 1
- 382 Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome. **2020**, 18, 121 23
- 381 Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescent Females. **2020**, 63, 544-552 4
- 380 Endocrine Pathophysiology. **2020**,
- 379 Hormonal Effects on Hair Follicles. **2020**, 21, 26
- 378 Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents. **2020**, 145, S210-S218 14
- 377 Circulating and Adipose Tissue miRNAs in Women With Polycystic Ovary Syndrome and Responses to High-Intensity Interval Training. **2020**, 11, 904 7
- 376 Mechanisms Underlying Absent Training-Induced Improvement in Insulin Action in Lean, Hyperandrogenic Women With Polycystic Ovary Syndrome. **2020**, 69, 2267-2280 5
- 375 Elevation of markers of endotoxemia in women with polycystic ovary syndrome. **2020**, 35, 2303-2311 6
- 374 Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil. **2020**, 151, 383-391 5
- 373 Response to Letter to the Editor: "Distribution of Body Hair in Young Australian Women and Associations with Serum Androgen Concentrations". *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, 5.6
- 372 Síndrome de ovarios policísticos. **2020**, 56, 1-18

371	Hair counting with deep learning. 2020 ,			1
370	Influence of endurance training-induced weight loss on the levels of ghrelin and obestatin of obese women with polycystic ovary syndrome. 2020 , 16, 703-711			0
369	Levonorgestrel vs combined oral contraceptive pills in treatment of female acne and hirsutism. 2020 , 33, e13700			0
368	Evaluation of quality of life of patients with hirsutism among Turkish women: A single-center cross-sectional study. 2020 , 19, 3053-3057			1
367	Androgenicity and fertility treatment in women with unexplained infertility. 2020 , 113, 636-641			4
366	Physical Exercise following bariatric surgery in women with Morbid obesity: Study protocol clinical trial (SPIRIT compliant). 2020 , 99, e19427			3
365	Adolescent polycystic ovary syndrome according to the international evidence-based guideline. 2020 , 18, 72			59
364	Menstrual patterns and self-reported hirsutism as assessed via the modified Ferriman-Gallwey scale: A cross-sectional study. 2020 , 248, 137-143			3
363	Inflammatory Markers in Women with Polycystic Ovary Syndrome. 2020 , 2020, 4092470			21
362	The role of androgen receptor CAG repeat polymorphism in androgen excess disorder and idiopathic hirsutism. 2020 , 43, 1271-1281			3
361	Anti-M ^u llerian Hormone and Ovarian Morphology in Women With Hypothalamic Hypogonadism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6		12
360	Serum Caspase-1 levels in women with polycystic ovary syndrome. 2020 , 59, 207-210			1
359	Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. 2020 , 16, 255-274			38
358	Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome: A Multicenter Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6		9
357	Obesity, Insulin Resistance, and Hyperandrogenism Mediate the Link between Poor Diet Quality and Ovarian Dysmorphology in Reproductive-Aged Women. 2020 , 12,			12
356	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6		8
355	Virilising ovarian tumour in a postmenopausal woman after bilateral oophorectomy. 2020 , 25, 1-5			
354	HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). 2020 , 36, 588-593			8

353	Impact of Bariatric Surgery on Clinical, Biochemical, and Hormonal Parameters in Women with Polycystic Ovary Syndrome (PCOS). 2020 , 30, 2294-2300	12
352	Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence. 2020 , 17, 812-825	16
351	The endocrine manifestations of spinal muscular atrophy, a real-life observational study. 2020 , 30, 270-276	4
350	Comparison of body mass index and metabolic parameters with serum vaspin levels in women with polycystic ovary syndrome. 2020 , 14, 137-139	4
349	Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. 2020 , 12, 66-71	12
348	Acupuncture or auricular electro-acupuncture as adjuncts to lifestyle interventions for weight management in PCOS: protocol for a randomised controlled feasibility study. 2020 , 6, 53	3
347	Improving reproductive function in women with polycystic ovary syndrome with high-intensity interval training (IMPROV-IT): study protocol for a two-centre, three-armed randomised controlled trial. 2020 , 10, e034733	3
346	Ovarian 25OH-vitamin D production in young women affected by polycystic ovary syndrome. 2020 , 43, 1623-1630	
345	Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome. 2020 , 36, 849-853	1
344	Association of decreased myonectin levels with metabolic and hormonal disturbance in polycystic ovary syndrome. 2020 , 36, 947-950	4
343	The effect of exercise as an intervention for women with polycystic ovary syndrome: A systematic review and meta-analysis. 2020 , 99, e19644	7
342	Decreased levels of spexin are associated with hormonal and metabolic disturbance in subjects with polycystic ovary syndrome. 2021 , 41, 408-413	4
341	Sexual function in women with androgen excess disorders: classic forms of congenital adrenal hyperplasia and polycystic ovary syndrome. 2021 , 44, 505-513	2
340	Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. 2021 , 41, 279-284	8
339	Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial. 2021 , 40, 870-878	6
338	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. 2021 , 24, 104-115	10
337	Reproductive Hormones and Anthropometry: A Follow-Up of PCOS and Controls From Perimenopause to Older Than 80 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 421-430	5
336	Quality of Life in Infertile Women with Polycystic Ovary Syndrome: a Comparative Study. 2021 , 28, 1901-1909	5

335	In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study. 2021 , 125, 105104		
334	Anti-Müllerian Hormone Levels in Adolescence in Relation to Long-term Follow-up for Presence of Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1084-e1095	5.6	2
333	The influence of infertility on sexual and marital satisfaction in Iranian women with polycystic ovary syndrome: a case-control study. 2021 , 26,		0
332	Encyclopedia of Pathology. 2021 , 1-2		
331	Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome. 2021 , 72, 400-410		7
330	Selected Disorders of the Endocrine and Metabolic System. 2021 , 1-18		
329	Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans (HAIR-AN) Syndrome Reflects Adipose Tissue Dysfunction ("Adiposopathy" or "Sick Fat") in Asian Indian Girls. 2021 , 237, 797-805		0
328	Positive and Negative Affect Changes during Gender-Affirming Hormonal Treatment: Results from the European Network for the Investigation of Gender Incongruence (ENIGI). 2021 , 10,		3
327	Assessment of Optimism in Women with Polycystic Ovary Syndrome: A Case Control-Study. 2021 , 18,		1
326	Racial and Ethnic Differences in Metabolic Disease in Adolescents With Obesity and Polycystic Ovary Syndrome. 2021 , 5, bvab008		3
325	Facial Hair Transplantation for Transgender Patients: A Literature Review and Guidelines for Practice. 2021 , 41, NP42-NP51		2
324	Why are Women With Polycystic Ovary Syndrome at Increased Risk of Depression? Exploring the Etiological Maze. 2021 , 13, e13489		1
323	Hyperandrogenic Anovulation: Differential Diagnosis and Evaluation. 2021 , 50, 1-10		1
322	Body Composition and Characterization of Skinfold Thicknesses from Polycystic Ovary Syndrome Phenotypes. A Preliminary Case-Control Study. 2021 , 18,		
321	Postmenopausal Hyperandrogenism: Evaluation and Treatment Strategies. 2021 , 50, 97-111		0
320	Absent Exercise-Induced Improvements in Fat Oxidation in Women With Polycystic Ovary Syndrome After High-Intensity Interval Training. 2021 , 12, 649794		2
319	The level of adhesion molecules in polycystic ovary syndrome. 2, 57-63		
318	CLINICAL PROFILE OF YOUNG ADULTS (18-24 YEARS) WITH POLYCYSTIC OVARY SYNDROME. 2021 , 1-3		

317	Polycystic ovary syndrome and reproductive health of women: a curious association. 2021 ,	5
316	Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. 2021 , 36, 1611-1620	4
315	A multi-center trial of exercise and testosterone therapy in women after hip fracture: Design, methods and impact of the COVID-19 pandemic. 2021 , 104, 106356	2
314	Exercise training and reproductive outcomes in women with polycystic ovary syndrome: A pilot randomized controlled trial. 2021 , 95, 332-343	8
313	Polycystic ovary syndrome and (pre)osteoarthritis: assessing the link between hyperandrogenism in young women and cartilage oligomeric matrix protein as a marker of cartilage breakdown. 2021 , 40, 4217-4223	3
312	A CROSS SECTIONAL STUDY OF POLY CYSTIC OVARIAN SYNDROME (PCOS) AMONGST ADOLESCENT GIRLS IN LUCKNOW.. 2021 , 3-5	
311	Sleep Habits of Women With Infertility. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e44146-e4436	6
310	Anthropometric Characteristics of Polycystic Ovary Syndrome and Their Associations with Insulin Resistance and Lipid Profile. 2021 , 11, 5395	1
309	Addressing important knowledge gaps about the disease burden of hirsutism. 2021 , 7, 243-245	
308	Urinary Metabolites Reveal Hyperinsulinemia and Insulin Resistance in Polycystic Ovarian Syndrome (PCOS). 2021 , 11,	4
307	Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women. 2021 , 46, 101756	
306	Prevalence of idiopathic hirsutism: A systematic review and meta-analysis. 2021 ,	0
305	Hirsutism and Menstrual Irregularity in a 16-year-old Girl. 2021 , 42, 449-452	
304	Unexpected Effects of Oral Isotretinoin in Adolescents With Acne Vulgaris. 2021 , 13, e17115	
303	Characterizing the role of facial hair in gender identity and expression among transgender men. 2021 ,	0
302	Fat intake pattern in women with polycystic ovary syndrome. 2021 ,	0
301	Prevalence of Hirsutism Among Reproductive-Aged African American Women. 2021 , 30, 1580-1587	2
300	The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis. 2021 , 14, 125	5

299	Are current cut-off values of 11-DOC in children useful for assessing suspected nonclassical congenital adrenal hyperplasia due to 11 β -hydroxylase deficiency?. 2021,	
298	Polycystic Ovarian Morphology in Normocyclic Non-hyperandrogenic Adolescents. 2021, 34, 610-616	5
297	Androgen excess in women. 2022, 810-823.e3	
296	Polycystic ovary syndrome. 2022, 824-837.e5	
295	Adolescent disorders. 2021, 909-938	
294	Abnormal Uterine Bleeding in the Adolescent. 2021,	
293	Gonadotrophin-releasing hormone analogues for hirsutism.	2
292	Hyperandrogenism in PCOS. 2009, 105-110	1
291	Polycystic Ovary Syndrome. 2010, 147-182	1
290	Hirsutism and Virilism in Women. 1987, 459-479	1
289	Polycystic Ovary Syndrome and Its Metabolic Complications. 2006, 255-276	1
288	Clinical Features of the Polycystic Ovary Syndrome. 2006, 155-167	1
287	Androgen-Secreting Adrenal and Ovarian Neoplasms. 2006, 75-84	2
286	Hair Growth Assessment Techniques. 2008, 125-157	15
285	Androgens and hair. 1998, 169-186	5
284	Hirsutism. 1990, 777-789	5
283	Die Nebennierenrinde. 1978, 286-422	5
282	Polyzystisches Ovarsyndrom (PCOS). 2020, 59-69	1

281	Clinical Investigations of the Contraceptive and Therapeutic Potential of Nafarelin. 1987 , 257-277	1
280	Disorders of Pituitary-Gonadal Function. 1984 , 233-272	1
279	Physiology and Pathology of the Female Reproductive Axis. 2011 , 581-660	11
278	Nitrogen-retaining steroids and their application in disease. 1965 , 2, 79-113	6
277	Polycystic ovary syndrome: clinical perspectives and management. 1999 , 54, 403-13	49
276	Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. 1996 , 134, 1057-1059	74
275	Post-adolescent acne: a review of clinical features. 1997 , 136, 66-70	127
274	Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. 2002 , 109, 973-981	82
273	Long-Term Gynecological Outcomes in Women with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. 2010 , 2010, 784297	12
272	Reduced uterine and ovarian size in adolescent girls born small for gestational age. 2000 , 47, 575-7	140
271	Levels of Neopterin and other Inflammatory Markers in Obese and Non-Obese Patients with Polycystic Ovary Syndrome. 2015 , 21, 2446-55	19
270	The Relationship Between Hearing Thresholds and Hyperandrogenism in Polycystic Ovary Syndrome. 2016 , 22, 4380-4385	3
269	A Case-Control Study on the Oxidative Status in Women with Polycystic Ovary Syndrome Treated with Clomiphene Citrate. 2019 , 25, 3910-3917	3
268	The Effect of Three Menstrual Cycle Phases on Adrenal Hormonal Dynamics and Etiologies of Hirsutism in Five Ethnic/Racial Female Populations. 1998 , 7, 23-34	1
267	Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study. 2015 , 10, e0138793	56
266	The Presence of Clitoromegaly in the Nonclassical Form of 21-Hydroxylase Deficiency Could Be Partially Modulated by the CAG Polymorphic Tract of the Androgen Receptor Gene. 2016 , 11, e0148548	8
265	Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III. 2017 , 12, e0173144	12
264	Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally. 2019 , 8, 616-624	8

263	[Insulin resistance and metabolic profile in lean and overweight/obese polycystic ovary syndrome patients]. 2006 , 50, 1026-33	6
262	[Difficulties and pitfalls in the diagnosis of polycystic ovary syndrome]. 2011 , 55, 6-15	6
261	Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome. 2016 , 16, 298-306	11
260	Prevalence of metabolic syndrome in four phenotypes of PCOS and its relationship with androgenic components among Iranian women: A cross-sectional study. 2020 , 18, 253-264	5
259	Perceived Stress Scale Among Adolescents with Polycystic Ovary Syndrome. 2020 , 12, 1253-1258	1
258	Evaluation of Ovaries in Patients with Polycystic Ovary Syndrome using Shear Wave Elastography. 2020 , 16, 578-583	3
257	Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. 2017 , 18, 17-21	50
256	Association of Glomerular Filtration Rate with Inflammation in Polycystic Ovary Syndrome. 2015 , 9, 176-82	8
255	Association of vitamin D receptor gene variants with polycystic ovary syndrome: A case control study. 2015 , 13, 793-800	8
254	Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. 2016 , 14, 743-754	10
253	Effect of Citrullus colocynthis hydro-alcoholic extract on hormonal and folliculogenesis process in estradiol valerate-induced PCOs rats model: An experimental study. 2017 , 15, 661-668	3
252	Facilitating and inhibiting factors related to treatment adherence in women with polycystic ovary syndrome: A qualitative study. 2017 , 15, 553-560	7
251	Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients. 2011 , 34, e178-82	3
250	Genotype, phenotype and hormonal levels correlation in non-classical congenital adrenal hyperplasia. 2011 , 34, 660-4	7
249	Relative associations of polycystic ovarian syndrome vs metabolic syndrome with thyroid function, volume, nodularity and autoimmunity. 2011 , 34, e259-64	8
248	Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. 2011 , 34, 685-91	8
247	Haplotype TGTG from SNP 45T/G and 276G/T of the adiponectin gene contributes to risk of polycystic ovary syndrome. 2013 , 36, 497-502	6
246	The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women. 2019 , 34, 374-381	8

245	Calpain-10 Polymorphism in Korean Women with Polycystic Ovary Syndrome. 2008 , 23, 319	1
244	Survey of Cutaneous Manifestations in Adolescents Suffering from Poly Cystic Ovarian Syndrome. 2012 , 5, 11-21	2
243	Familial Background of Complex Diseases in PCOS Probands of South Indian Population. 2012 , 5, 50-55	10
242	Analysis of oxidative stress status through MN test and serum MDA levels in PCOS women. 2014 , 17, 574-7	15
241	Hirsutism: evaluation and treatment. 2010 , 55, 3-7	27
240	Endocrinal and autoimmune linkage: Evidences from a controlled study of subjects with polycystic ovarian syndrome. 2016 , 9, 18-22	10
239	Evaluation of Long-pulsed 1064 nm Nd:YAG Laser-assisted Hair Removal vs Multiple Treatment Sessions and Different Hair Types in Indian Patients. 2008 , 1, 75-9	10
238	Autistic Trait, Empathy, and Attention-Deficit/Hyperactivity Symptoms in Women with Idiopathic Hirsutism. 2015 , 7, 113-8	2
237	Development of a scoring system using a statistical model to predict cure status in patients with cutaneous leishmaniasis. 2017 , 22, 1	20
236	Age and BMI Adjusted Comparison of Reproductive Hormones in PCOS. 2012 , 1, 132-6	7
235	Hyperandrogenism â approach and management. 2019 , 6, 16	2
234	Modified Ferriman-Gallwey Score in Hirsutism and its Association with Metabolic Syndrome. 2017 , 9, 7-13	20
233	The Effect of Metformin Treatment on the Serum Levels of Homocysteine, Folic Acid, and Vitamin B12 in Patients with Polycystic Ovary Syndrome. 2017 , 10, 95-101	18
232	Prevalence of hypothyroidism and thyroid autoimmunity in polycystic ovarian syndrome patients: A North Indian study. 2019 , 16, 55	2
231	Anti-M�llerian Hormone and Inhibin-A, but not Inhibin-B or Insulin-Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. 2016 , 8, 288-97	12
230	Association of decreased C1q/tumor necrosis factor-related protein-5 levels with metabolic and hormonal disturbance in polycystic ovary syndrome. 2019 , 20, 89-96	5
229	Is anti-Mullerian hormone a good diagnostic marker for adolescent and young adult patients with Polycystic ovary syndrome?. 2015 , 12, 199-204	8
228	Gestational Diabetes Mellitus and Metabolic Disorder Among the Different Phenotypes of Polycystic Ovary Syndrome. 2017 , 32, 214-220	10

227	Hirsutism in Saudi females of reproductive age: a hospital-based study. 2008 , 28, 28-32	14
226	Metabolic and carbohydrate characteristics of different phenotypes of polycystic ovary syndrome. 2016 , 17, 201-208	4
225	Relationship Between the Clinical and Biochemical Findings of Polycystic Ovary Syndrome and Depression and Anxiety. 2016 , 53, 366-367	1
224	The changing face of hirsutism. 1992 , 156, 148	3
223	The Effect of Exercise in PCOS Women Who Exercise Regularly. 2010 , 1, 35-40	7
222	The Polycystic Ovary Syndrome Health-Related Quality-of-Life Questionnaire: Confirmatory Factor Analysis. 2018 , 16, e12400	5
221	Anthropometric and Biochemical Characteristics of Polycystic Ovarian Syndrome in South Indian Women Using AES-2006 Criteria. 2014 , 12, e12470	26
220	Comparison of Metformin and Simvastatin Administration in Women With Polycystic Ovary Syndrome Before Intra-Cytoplasmic Sperm Injection Cycle: A Prospective, Randomized, Clinical Trial Study. 2015 , 17, e20082	4
219	Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. 2012 , 67, 283-7	11
218	Multi-Parameter Approach for Evaluation of Genomic Instability in the Polycystic Ovary Syndrome. 2015 , 16, 7129-38	3
217	Endotrophin as a novel marker in PCOS and its relation with other adipokines and metabolic parameters: a pilot study. 2021 , 12, 20420188211049607	1
216	Modern approach to the treatment of patients with androgen-dependent dermatopathies. 2021 , 94-100	
215	The Comparison of Gender Dysphoria, Body Image Satisfaction and Quality of Life Between Treatment-Naive Transgender Males With and Without Polycystic Ovary Syndrome.	1
214	Hirsutism. 2000 , 241-245	
213	Weibliche Gonaden. 2001 , 155-240	
212	Avalia ^o da utilidade do est ^o rnilo agudo das gonadotrofinas e dos ester ^o ides ovarianos com an ^o ligo do horm ^o bio liberador de gonadotrofinas no diagn ^o stico diferencial do hiperandrogenismo ovariano funcional. 2003 , 47, 55-61	
211	Hair Metrology. 2004 , 255-270	
210	Spezielle kosmetische Behandlungsverfahren. 2004 , 185-288	

- 209 Comparison of The Effects of Metformin and Goserelin in Patients with Polycystic Ovary Syndrome. **2004**, 1,
- 208 Obesity, Polycystic Ovary Syndrome, and Mood Disorders. **2006**, 189-216
- 207 [Hirsutism: differential diagnosis]. **2006**, 50, 1108-16 1
- 206 Hyperandrogenism. **2007**, 979-999
- 205 Clinical Evaluation of Polycystic Ovary Syndrome. **2007**, 417-429
- 204 Gyn^kologische Erkrankungen. **2007**, 1095-1110
- 203 Polycystic Ovary Syndrome. **2007**, 455-458
- 202 Hirsutism and Hypertrichosis. **2008**, 211-224
- 201 Hirsutism in Kashmir: an etiological study. **2009**, 54, 80-2 4
- 200 St^kungen des Androgenhaushalts. **2009**, 385-417
- 199 Clinical Manifestations of PCOS. **2009**, 3-13
- 198 Trichologie. **2009**, 624-630
- 197 Endokrinologische St^kungen an Haut und Haaren. **2009**, 419-441
- 196 Female Reproductive Organ Testing. **2009**, 399-425
- 195 Androgen Excess and Hirsutism. 404-410
- 194 Hair Removal. **2011**, 61-78
- 193 Syndrome of hyperandrogenism in girls of pubertal age. **2010**, 56, 48-54 1
- 192 The Ovary and Polycystic Ovary Syndrome. **2011**, 289-300

191 Hirsutism and virilization. **2011**, 382-390

190 Gonadotrophin-releasing hormone analogues for hirsutism.

189 Polycystic ovary syndrome. **2011**, 117-126

188 Le syndrome des ovaires polymicrokystiques. **2012**, 149-160

187 Predictors of abnormal glucose tolerance among women with polycystic ovary syndrome. **2012**, 55, 477

186 Literatur. **2012**, 215-227

185 Hyperandrogen^mie. **2013**, 53-64

184 Kinder- und Jugendgyn^kologie. **2013**, 949-970

183 Hyperandrogenism. **2013**, 849-868

182 Endocrine Disorders in Adolescence. **2013**, 657-671

181 Hirsutism. **2013**, 65-73

180 Androgen Secreting Steroid Cell Tumor of the Ovary Represented with Postmenopasal Bleeding and Extensive Hirsutism. **2013**, 1, 93-98

179 Psychological Problems in the Treatment of Idiopathic Hirsutism with the Antiandrogen Cyproterone Acetate. **1982**, 144-145

178 Adrenal Cortex. **1986**, 349-486

4

177 Erfahrungen mit einem Fragebogen zum K^opererleben. **1986**, 220-231

2

176 Skin and hormone. 6. Hormone therapy for acne and hypertrichosis. Mainly on antiandrogens.. **1986**, 48, 1101-1107

175 Hirsutism. **1988**, 371-391

174 The Endocrine and Metabolic Systems. **1988**, 412-438

- 173 Results Obtained with a Body Experience Questionnaire. **1988**, 200-210
- 172 Methods for Assessing the Effect of Drugs on Hair and Nails. **1989**, 27-31
- 171 Antiandrogens: Clinical Aspects. **1990**, 827-886 0
- 170 Oligomenorrhoea and hirsutism; the polycystic ovary syndrome. **1991**, 73-88
- 169 Androgens in Women: Their Effects on Lipid and Carbohydrate Metabolism. **1991**, 81-105
- 168 Störungen des Androgenhaushalts. **1992**, 249-287
- 167 The prevalence of hirsutism in Iraqi females. **1992**, 12, 453-5
- 166 Hirsutism and Virilism. **1993**, 287-294
- 165 Störungen des Androgenhaushalts. **1998**, 315-366
- 164 Gonadotrophin-releasing hormone analogues for hirsutism.
- 163 [Importance of the interdisciplinary, evidence-based diagnosis of polycystic ovary syndrome]. **2014**, 155, 1175-88
- 162 Scoring-Systeme in der Endokrinologie. **2015**, 245-253
- 161 IS SUBCLINICAL HYPOTHYROIDISM IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME ASSOCIATED WITH BMI?. **2016**, 12, 431-436 6
- 160 Patients and Methods. **2016**, 1-3
- 159 "Hormonal Wedge Resection" An Effective Treatment Method of Anovulatory Infertility Associated with Polycystic Ovary Syndrome. **2016**, 165-183
- 158 Dependence of Fetal Hair and Sebaceous Glands on Fetal Adrenal Cortex and Possible Control from Epidermal Merkel Cells and Adrenal Medulla. **2016**, 215-221
- 157 Evaluation and Management of Hirsutism in Postmenopausal Women. **2017**, 209-219 1
- 156 Clinical Efficacy of Ayurvedic Formulations Rajahpravartini Vati, Varunadi Kashaya and Kanchanar Guggulu in the Management of Polycystic Ovary Syndrome: A Prospective, Open-label, Multicenter Study. **2017**, 1, 90-98 0

155 Hyperandrogenämie - Diagnostik und Therapiekonzepte. **2017**, 187-196

154 Hirsutism. **2017**, 1443-1447

153 Clinical Safety of Selected Ayurvedic Formulations in Iron Deficiency Anemia. **2017**, 1, 99-107

152 Polycystic Ovarian Syndrome (PCOS) this Mysterious Disease. **2017**, 4,

151 Clinical Profile of Patients with Polycystic Ovarian Syndrome in Nepal. **2017**, 4,

150 A STUDY ON CLINICAL PROFILE OF PATIENTS WITH HIRSUTISM. **2017**, 6, 2726-2729

149 Marked hyperandrogenicity in a 60-year-old woman. **2017**, 2017,

1

148 Scoring-Systeme in der Endokrinologie. **2018**, 273-287

147 Large-Scale Genome-Wide Meta Analysis of Polycystic Ovary Syndrome Suggests Shared Genetic Architecture for Different Diagnosis Criteria.

146 Le syndrome des ovaires polykystiques. **2019**, 159-177

145 Bei adipösen Mädchen mit Hirsutismus auch an PCOS denken. **2019**, 31, 48-53

144 IPL for Hair Removal. **2020**, 75-92

143 Significant reduction of T3 hormone and increase in the occurrence of non-thyroid illness syndrome in ovarian cyst and polycystic ovary syndrome patients. **2019**, 178,

142 Endocrine Indices of PCOS in Women with Polycystic Ovaries but without Diagnostic Features of PCOS: A Study of an Infertility Clinic Population. **2020**, 10, 275-283

141 Clinical and diagnostic manifestations in women of reproductive age having both hyperthyroidism and hyperandrogenism. **2020**, 13, 279-288

140 The role and importance of auxiliary tests in differential diagnosis in patients with mildly high basal 17-OH-progesterone levels in the evaluation of hirsutism. **2020**, 50, 1976-1982

o

139 Clinical Obstetrics & Gynecology: Polycystic Ovary Disease Ethnicity, Diversity, and Psychosocial Ramifications. **2021**, 64, 76-82

o

138 Het polycystisch ovariumsyndroom: actuele richtlijnen voor diagnose in de eerste lijn en vruchtbaarheidsbehandeling. **2020**, 76,

137	Relationship of subclinical hypothyroidism and obesity in polycystic ovarian syndrome patients. 2020 , 9, 147-150	4
136	Reproductive Organ Signs. 2020 , 127-149	
135	Polycystic Ovary Syndrome. 2020 , 83-97	0
134	Prevalence of Cutaneous Disorders in Patients with Polycystic Ovary Syndrome. 2020 , 10, 1246-1264	
133	Polycystic Ovarian Syndrome (PCOS). 2020 , 631-662	
132	Psychometric Properties of the Iranian Version of Physical Disability Sexual and Body Esteem Questionnaire in Women with Polycystic Ovary Syndrome. 2020 , 1, 5-10	1
131	Creating a Survey Instrument for Self-Assessed Menstrual Cycle Characteristics and Androgen Excess.	0
130	Systematic review of finasteride effect in women with hirsutism. 2021 , 67, 1043-1049	
129	Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. 2021 , 13,	2
128	Peculiarities of formation of secondary sexual characteristics and menstrual function in girls with hyperandrogenism during puberty. 2020 , 14, 211-217	
127	Störungen des Androgenhaushalts. 2005 , 343-389	1
126	Fuzzy Logic-Based Tools for the Acquisition and Representation of Knowledge in Biomedical Applications. 1994 , 529-551	1
125	Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. 2002 , 109, 973-81	30
124	Pediatric Hyperandrogenism and the Polycystic Ovary Syndrome in Adolescence. 2006 , 235-246	
123	Hirsutism. 2008 , 357-377	
122	Ästhetische Endokrinologie. 275-288	
121	Androgens. 2009 , 63-86	
120	Hirsutism in young adolescent girls. 1986 , 15, 522-8	

119	Increased fetuin-B levels are associated with carotid intima media thickness and hormonal-metabolic disturbances in women with polycystic ovary syndrome.	
118	Acne, Hirsutism, and Other Signs of Increased Androgens. 2021 , 85-94	
117	EFFECT OF POLY-CYSTIC OVARIAN SYNDROME ON SELF-ESTEEM AND BODYIMAGE AMONG ADOLESCENT GIRLS ATTENDING ADOLESCENT CLINIC IN A TERTIARY CARE CENTRE. 2020 , 49-52	0
116	Hirsutism. 1985 , 12, 649-674	2
115	Clinical features of schizophrenia in a woman with hyperandrogenism. 1997 , 22, 56-60	7
114	Approach to patients with hirsutism. 1996 , 165, 386-91	3
113	What we see most, we understand least. 1996 , 165, 392-3	
112	Some factors affecting hair growth in man. 1965 , 58, 802-4	1
111	HAIR AND PHYSIOLOGICAL BALDNESS. 1965 , 92, 1345-8	
110	The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome. 2007 , 28, 79-92	9
109	Virilizing ovarian steroid cell tumor in a 40 year old South Indian female: a case report. 2009 , 2, 7521	1
108	Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. 2011 , 16, 999-1005	12
107	Hirsutism and body mass index in a representative sample of Iranian people. 2012 , 8, 43-54	4
106	The relationship between Anti-M ^u llerian hormone and other reproductive parameters in normal women and in women with polycystic ovary syndrome. 2013 , 6, 146-50	5
105	Evaluation of Fenugreek (Trigonella foenum-graceum L.), Effects Seeds Extract on Insulin Resistance in Women with Polycystic Ovarian Syndrome. 2013 , 12, 475-81	19
104	The effect of fennel (Foeniculum vulgare) gel 3% in decreasing hair thickness in idiopathic mild to moderate hirsutism, A randomized placebo controlled clinical trial. 2014 , 5, 26-9	4
103	Iranian version of modified polycystic ovary syndrome health-related quality of Life questionnaire: Discriminant and convergent validity. 2013 , 11, 753-60	10
102	Body image satisfaction and self-esteem status among the patients with polycystic ovary syndrome. 2013 , 11, 829-36	33

101	Relationship between serum cystatin C and polycystic ovary syndrome. 2013 , 11, 71-6	5
100	Health-related quality of life and its relationship with clinical symptoms among Iranian patients with polycystic ovarian syndrome. 2013 , 11, 371-8	20
99	Race, rather than skin pigmentation, predicts facial hair growth in women. 2014 , 7, 24-6	5
98	Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women with non-classic congenital adrenal hyperplasia (NCAH). 2012 , 10, 307-14	4
97	Sexual Functioning among Married Iranian Women with Polycystic Ovary Syndrome. 2014 , 8, 273-80	10
96	Oxidative stress and anti-oxidant defense system in Iranian women with polycystic ovary syndrome. 2015 , 13, 373-8	21
95	Association of vitamin D receptor gene variants with polycystic ovary syndrome: A case control study. 2015 , 13, 793-800	10
94	Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. 2016 , 14, 743-754	8
93	Clinical and Biochemical Characteristics in PCOS Women With Menstrual Abnormalities. 2016 , 10, 184-190	4
92	Dehydroepiandrosterone-Sulfate, Insulin Resistance and Ovarian Volume Estimation in Patients With Polycystic Ovarian Syndrome. 2017 , 11, 24-29	6
91	Effect of Citrullus colocynthis hydro-alcoholic extract on hormonal and folliculogenesis process in estradiol valerate-induced PCOs rats model: An experimental study. 2017 , 15, 661-668	5
90	Facilitating and inhibiting factors related to treatment adherence in women with polycystic ovary syndrome: A qualitative study. 2017 , 15, 553-560	3
89	Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study. 2018 , 148, S151-S155	1
88	Efficacy of Metformin in the Treatment of Acne in Women with Polycystic Ovarian Syndrome: A Newer Approach to Acne Therapy. 2019 , 12, 34-38	5
87	Polycystic Ovary Syndrome and Gender Identity. 2020 , 93, 529-537	3
86	IMPORTANCE OF HAIR GROWTH IN HISUTISM: DIAGNOSIS AND TREATMENT. 43-49	
85	Kinder- und Jugendgyn�kologie. 2021 , 1-21	
84	Selected Disorders of the Endocrine and Metabolic System. 2022 , 1795-1812	

- 83 Levels of Trace Elements in Erythrocytes as Endocrine Disruptors in Obese and Nonobese Women with Polycystic Ovary Syndrome.. **2022**, 19, 0
- 82 Assessment of the Parameters of Oxidative Stress Depending on the Metabolic and Anthropometric Status Indicators in Women with PCOS.. **2022**, 12, 1
- 81 Associations Between Sex Hormone Levels and Autistic Traits in Infertile Patients With Polycystic Ovary Syndrome and Their Offspring.. **2021**, 12, 789395 0
- 80 Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients.. **2022**, 20, 6 1
- 79 Ayurveda management of infertility associated with Poly Cystic Ovarian Syndrome: A case report.. **2021**, 13, 100513 0
- 78 Cardiovascular Risk Factors and Subclinical Atherosclerosis in Greek Adolescents with Polycystic Ovary Syndrome: Its Relationship with Body Mass Index.. **2021**, 9, 0
- 77 Recent highlights of research on androgen receptors in women. **2017**, 21, 7-12
- 76 Prevalence of Polycystic Ovarian Syndrome, Phenotypes and their Ovulation Response to Sequential Letrozole Dose Escalation among Infertile Women at a Tertiary Care Centre in Southern India.. **2022**, 15, 42-50
- 75 Is Enriched in Gut Microbiome of Kashmiri Women with Polycystic Ovary Syndrome.. **2022**, 13, 0
- 74 Which laboratory/ultrasonographic parameters affect the severity of hirsutism?. **2022**,
- 73 Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study. **2022**, 7, 63-69
- 72 Analysis of 2-Arachidonoylglycerol Levels in Polycystic Ovary Syndrome in the Context of Hormonal and Metabolic Alterations and Across the Classical Phenotypes.. **2022**, 0
- 71 Facial hypertrichosis after isotretinoin therapy: Is it a side effect or coincidence?. **2022**, 56, 7-11
- 70 Circulating Level of Serum Secreted Frizzled-Related Protein 5 Decreases in Polycystic Ovary Syndrome.. **2022**, 1-9
- 69 Correlation between the Physical Signs, Clinical Parameters, and the Quality of Life in Young Women with Polycystic Ovarian Syndrome: An Explorative Study. **2022**, 14, 17-21
- 68 Is idiopathic hirsutism idiopathic?. **2022**, 531, 17-24 0
- 67 PKOS Hastalarında Y^h İsek Kan Basıncı ve Sıktır ve Bunun Klinik ve Laboratuvar Parametrelerle İlişisi. **2021**, 10, 173-179
- 66 COMPARISON OF POLYCYSTIC OVARIES IN OBESE AND NON-OBESE PATIENTS. **2021**, 4,

- 65 Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Female Pattern Hair Loss. **2022**, 205-231
- 64 A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome.. **2022**, 0
- 63 Quantitative Changes in White Blood Cells: Correlation with the Hallmarks of Polycystic Ovary Syndrome.. **2022**, 58, 1
- 62 Prepubertal and pubertal gonadal morphology, expression of cell lineage markers and hormonal evaluation in two 46,XY siblings with 17 β -hydroxysteroid dehydrogenase 3 deficiency.. **2022**, 0
- 61 Association of FTO gene variant rs9939609 with hyperandrogenemia and fasting glucose levels in South Indian women with polycystic ovarian syndrome. **2022**, 23,
- 60 Correlation between genotype and hormonal levels in heterozygous mutation carriers and non-carriers of 21-hydroxylase deficiency. **2011**, 34, 498-501 3
- 59 Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome. **2012**, 35, 553-6 2
- 58 Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. **2012**, 35, 905-10 13
- 57 Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. **2013**, 36, 478-84 6
- 56 Hyperandrogenism and Polycystic ovary syndrome: Effects in pregnancy and offspring development.. **2022**, e1558
- 55 The Classification of Polycystic Ovary Syndrome Informed by the International Guideline 2018. **2022**, 45-51
- 54 Missbrauch von Anabolen Androgenen Steroiden (AAS). **2021**, 1-14
- 53 Distinctive features of steroid hormone metabolism in female patients with androgenic alopecia. **2013**, 89, 27-32
- 52 The effects of metformin on hyperandrogenism and menstrual functions in insulin resistant adolescents with PCOS.
- 51 Polyzystisches Ovarsyndrom. **2022**, 365-374
- 50 Are STK11 polymorphisms a predictor of the response to metformin in polycystic ovarian syndrome?. **2022**, 17,
- 49 Type 2 Diabetes Precursors in Community Dwelling Asian Indian Adult Youth.
- 48 Androgenisierung: Diagnostik und Therapie â Akne vulgaris, Hirsutismus, female pattern hair loss. **2022**, 1-33

- 47 The role of ERK-1 and ERK-2 gene polymorphisms in PCOS pathogenesis. **2022**, 20, 0
- 46 The relation of dermcidin with insulin resistance and inflammation in women with polycystic ovary syndrome. **2022**, 68, 820-826 0
- 45 Effect of Acupressure on Health-Related Quality of Life in Patients with Polycystic Ovarian Syndrome: A Randomized Clinical Trial. **2022**, 2022, 1-10
- 44 SERUM SCLEROSTIN AND DICKKOPF-1 LEVELS IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. **2022**, 23, 252-256
- 43 Regional variability of modified Ferriman-Gallwey scoring in premenopausal healthy women in Southern Turkey. 1-6 0
- 42 The Role of Oxidative Stress in the Risk of Cardiovascular Disease and Identification of Risk Factors Using AIP and Castelli Atherogenicity Indicators in Patients with PCOS. **2022**, 10, 1700 1
- 41 Cyclosporine-induced hirsutism. 1-1
- 40 Evaluation of Hormonal Profile and Ovarian Morphology among Adolescent Girls with Menstrual Irregularities in a Tertiary Care Centre at Central India. **2022**, 2022, 1-8 0
- 39 Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo.
- 38 Hirsutism, Normal Androgens and Diagnosis of PCOS. **2022**, 12, 1922 2
- 37 Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial. 1-5 1
- 36 Polikistik over sendromlu obez olmayan kadınlarda progesteron ve progesteron kaynaklı blok edici faktör (PIBF) düzeyleri. **2022**, 47, 1114-1120 0
- 35 Probiotic effects on sexual function in women with polycystic ovary syndrome: a double blinded randomized controlled trial. **2022**, 22, 0
- 34 An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options. **2022**, 18, 174550572211179 0
- 33 Polycystic Ovary Syndrome in Adolescence. **2022**, 40, e1-e8 0
- 32 The effect of hyperandrogenism and obesity on mindfulness and metacognition in adolescents with polycystic ovary syndrome. **2022**, 25, 911-921 0
- 31 Ovarian Volume as an Independent Marker for Metabolic Dysfunction in Women with Suspected Androgen Excess. **2022**, 0
- 30 SÍNDROME DO OVÁRIO POLICÍSTICO ASSOCIADA À OBESIDADE: MECANISMOS FISIOPATOLÓGICOS E IMPLICAÇÕES CLÍNICAS -UMA REVISÃO INTEGRATIVA. **2022**, 2, e29188 0

- 29 Evaluation of circulating microRNA profiles in Brazilian women with polycystic ovary syndrome: A preliminary study. **2022**, 17, e0275031
- 28 Cohort profile: the Swedish Maternal Microbiome project (SweMaMi) â assessing the dynamic associations between the microbiome and maternal and neonatal adverse events. **2022**, 12, e065825
- 27 WiedemannâSteiner Syndrome: Case Report and Review of Literature. **2022**, 9, 1545
- 26 Predictive factors of Sexual Quality of Life in women with polycystic ovary syndrome: a path analysis.
- 25 Effects of Androgens on the Thickness of Retinal Layers in Transgender Men and in Women with Polycystic Ovarian Syndrome.
- 24 Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI).
- 23 Hirsutism. **2022**, 365-366
- 22 Polikistik Over Sendromlu Kad nlarda  ks t n Direnci ile Serum Copeptin D zeyi Aras ndaki  zgi.
- 21 Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo. **2022**, 22,
- 20 Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.
- 19 Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women. **2022**, 22,
- 18 Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
- 17 Comparison of image-based modified Ferriman-Gallway score evaluation with in-person evaluation: an alternative method for hirsutism diagnosis.
- 16 Genetic variations in OLR1 gene associated with PCOS and atherosclerotic risk factors. 108155892211418
- 15 PCOS â Kinderwunsch und Schwangerschaft. **2023**, 148, 34-39
- 14 Update zur Pathophysiologie, Diagnostik und Behandlung des Syndroms polyzystischer Ovarien in der Adoleszenz.
- 13 Hirsutism. **2016**, 1-5
- 12 Hirsutism. **2023**, 57-61

- 11 Effect of Laser-Assisted Hair Removal (LAHR) on the Quality of Life and Depression in Hirsute Females: A Single-Arm Clinical Trial. **2022**, 13, e46 ○
- 10 Adolescent PCOS: a postpubertal central obesity syndrome. **2023**, 29, 354-363 ○
- 9 Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor- α (TNF- α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naïve PCOS women. **2023**, 23, Reproductive Gesundheit. **2023**, 59-84 ○
- 8 Reproduktive Gesundheit. **2023**, 59-84 ○
- 7 Frauengesundheit â€“Frauenmedizin. **2023**, e1-e39 ○
- 6 A MODERN VIEW OF THE POLYCYSTIC OVARIAN SYNDROME. **2020**, 1, 5-12 ○
- 5 Pre-pregnancy complications - associated factors and wellbeing in early pregnancy: a Swedish cohort study. **2023**, 23, Current Guidelines for Diagnosing PCOS. **2023**, 13, 1113 ○
- 4 Current Guidelines for Diagnosing PCOS. **2023**, 13, 1113 ○
- 3 Epilation and depilation in the genital area â€“motivation, methods, risks and recommendations from a dermatological point of view. ○
- 2 Diagnostic criteria for polycystic ovary syndrome. **2024**, 61-74 ○
- 1 Unexpectedly high mutation rate of cyp11b1 compared to cyp21a2 in randomly-selected turkish women: a large screening study. ○